24 June 2024
Patria Private Equity Trust
plc
Legal Entity Identifier (LEI):
2138004MK7VPTZ99EV13
HALF YEARLY
REPORT FOR THE SIX MONTHS ENDED 31 MARCH 2024
FINANCIAL
HIGHLIGHTS
|
Six months ended
|
Year ended
|
Six months ended
|
|
31 March 2024
|
30 September 2023
|
31 March 2023
|
Net Asset Value Total
Return*+
|
2.0%
|
5.4%
|
3.0%
|
Share Price Total
Return*+
|
22.9%
|
11.7%
|
2.3%
|
FTSE All - Share Index
Total Return
|
6.9%
|
13.8%
|
12.3%
|
|
|
|
|
|
As at
|
As at
|
As at
|
|
31 March 2024
|
30 September 2023
|
31 March 2023
|
Net Asset
Value
|
£1,203.7m
|
£1,195.6m
|
£1,181.4m
|
Share Price
|
535.0p
|
442.0p
|
412.0p
|
Expense
Ratio*+
|
1.06%
|
1.06%
|
1.05%
|
* Considered to
be an Alternative Performance Measure.
+ A Key Performance Indicator by which the performance
of the Manager is measured by the Board.
HIGHLIGHTS TO 31 MARCH
2024
· Performance - NAV
total return ('NAV TR') for the six months to 31 March 2024 was
2.0%. The valuation of the underlying portfolio increased by 4.4%
during the period in underlying currency terms.
· Investment
Activity - Three new primary fund
commitments (£63.9 million), four new direct investments (£25.7
million), three follow-on investments in existing direct
investments (£9.7 million) and one fund secondary investment (£8.8
million) during the period, totalling £108.2 million (31 March
2023: £140.8 million).
· Direct
Investments - The direct investment
portfolio has now reached a portfolio of 30 separate underlying
companies and 22% of portfolio NAV (30 September 2023: 26 separate
underlying companies and 19% of portfolio NAV).
· Cashflows
- The portfolio generated distributions of £61.0
million (31 March 2023: £83.6 million) and had total drawdowns of
£86.9 million (31 March 2023: £104.4 million).
· Outstanding
Commitments - Outstanding
commitments at the period-end amounted to £663.8 million (30
September 2023: £652.0 million). The overcommitment ratio of 35.9%
(30 September 2023: 35.2%) was at the lower end of the Company's
target range (30-75%).
· Balance Sheet &
Liquidity - Cash and cash
equivalents of £27.4 million (30 September 2023: £9.4 million) and
£163.3 million remaining undrawn of its £300.0 million revolving
credit facility (30 September 2023: £197.7 million), totalling
£190.7 million of available resources.
Patria Private
Equity Trust plc ('PPET') is an investment trust with a premium
listing on the London Stock Exchange.
PPET provides investors with exposure to leading
private equity funds and private companies, mainly in Europe. It
invests in private equity funds by making primary commitments and
secondary purchases, and it makes direct investments into private
companies. Its investment objective is to achieve long-term total
returns for investors and its policy is to maintain a broadly
diversified portfolio by country, industry sector, maturity and
number of underlying investments.
Patria Capital Partners LLP, a wholly owned
subsidiary of Patria Investments Limited, is PPET's alternative
investment fund manager ('AIFM') and Manager (the 'Investment
Manager' or the 'Manager').
Introduction
Patria Investments Limited.
Patria Investments Limited ('Patria'), which
acquired the Company's Manager in April 2024, is a leading
alternative investment firm with over 35 years of specialised
experience in key resilient sectors. Patria has been listed
on the NASDAQ index since 2021. Its unique approach combines its
knowledge of investment leaders, sector experts and companies'
managers, with on-the-ground local experience. With over U$40
billion pro forma assets under management and a global presence, it
provides attractive and consistent returns in long-term investment
opportunities, while creating sustainable value for the regions
where it operates.
CHAIR'S
STATEMENT
Introduction
I am delighted to present the Half-Yearly Report
for Patria Private Equity Trust plc ('PPET' or 'the Company'), for
the six months to 31 March 2024 (the 'Period').
Whilst the past six months have continued to be
relatively subdued in terms of private equity market activity,
carrying on from where we left off at the end of the last financial
year, I was delighted to see PPET's strong share price performance.
During the Period, PPET delivered a share price total return of
22.9%, assuming dividend reinvestment. I believe that the buyback
programme introduced by the Board in January 2024 has helped to
support the improved performance of the share price up to 31 March
2024.
PPET has also continued to perform resiliently
from an investment point of view, demonstrating the effectiveness
of its investment strategy and the quality of its underlying
portfolio of growing, cash generative, mid-market private
companies.
Manager and
Name Change
In October 2023, abrdn plc ('abrdn') announced
the sale of its European-headquartered Private Equity business,
which included the Company's investment manager, then called abrdn
Capital Partners LLP and now called Patria Capital Partners LLP, to
an indirect subsidiary of Patria Investments Limited ('Patria'), a
global alternative asset manager listed on the NASDAQ
index.
The Board undertook extensive due diligence on
the proposed transaction with abrdn, Patria and PPET's Manager, to
fully understand the impact of the sale, and what it meant for
PPET's shareholders.
After several months of detailed work and the
completion of the due diligence exercise, I am delighted that the
Board was able to consent to the transaction by waiving the
'Manager Change of Control' provisions set out in PPET's Investment
Management Agreement. During our work, the Board received
assurances from Patria and the Manager that there will be: (i) no
change to the management and administration services which are
provided to PPET; (ii) no change to PPET's investment management
process; and (iii) no change to the personnel managing
PPET.
Importantly, we also received comfort that the
transaction will be cost neutral for PPET - there are not expected
to be additional costs to shareholders because of it.
The sale completed at the end of April 2024, at
which point the Company changed its name from abrdn Private Equity
Opportunities Trust plc to Patria Private Equity Trust
plc.
I know I speak for the entire Board when I say
that we are excited to continue to work with PPET's management team
and begin working with the wider team at Patria. I believe this
transaction will prove to be in the best interests of PPET
shareholders, with a re-energised management team backed by a
supportive, private markets-specialist in Patria. We have included
further information on Patria and its capabilities in the interim
accounts.
Share Price and
Investment Performance
During the Period, PPET's share price total
return was 22.9% and the share price discount to NAV at 31 March
2024 narrowed to 31.8% (30 September 2023: 43.2%), with the
discount ranging between 26.8% and 45.4%. The share price
total return outperformed the total return from the FTSE All-Share
Index, PPET's comparator index, of 6.9%. PPET's share price total
return has now outperformed the FTSE All-Share Index over 1, 3, 5
and 10 years, and since the inception of the Company in
2001.
As mentioned earlier, the Board announced a
buyback programme in January 2024. As at 31 March 2024, PPET had
bought back 385,491 of its ordinary shares into treasury, equating
to an aggregate investment of £2.0m. The programme, which is being
funded by a portion of the proceeds from the partial sale of PPET's
direct investment in Action, was instigated by the Board to take
advantage of PPET's share price discount and provide a compelling
investment for PPET shareholders. However, the programme has also
had the added impact of contributing to the short-term demand for
PPET shares and consequently helping to drive share price
performance during the period.
Turning to the performance of PPET's investment
portfolio, PPET has delivered resilient NAV performance during the
Period, with a NAV per share total return of 2.0% and net assets at
£1,203.7 million. The sharp rise in interest rates in 2022 and 2023
caused uncertainty in the private equity market, with buyers and
sellers differing in price expectations and dealmaking activity
falling from the record highs seen in 2021 and H1 2022. In that
context, PPET's strong performance is testament to PPET's
investment strategy, which has remained consistently focused on
partnering with a focused cohort of high-quality private equity
firms, predominately in the European mid-market.
PPET's underlying portfolio of private companies
consists of businesses that are often amongst the market leaders in
resilient, less cyclical sub-sectors and, importantly, the vast
majority are growing, profitable and cash generative. For example,
the top 50 portfolio companies by value in PPET, which equate to
38.2% of NAV, experienced average earning growth over the last
twelve-months ('LTM') of 22.4% at 31 March 2024.
Further detail on the performance of the
underlying portfolio of investments during the period can be found
in the Investment Manager's Review.
Commitments,
Investments and Distributions
PPET continues to employ a consistent, long-term
approach to new investment activity and capture exposure to the
latest vintages of private equity investments, whilst also being
prudent and considering the current market conditions. During the
Period, PPET made new commitments totalling £108.2 million (31
March 2023: £140.8 million). Specifically, PPET made three new
primary fund commitments (£63.9 million), four new direct
investments into private companies (£25.7 million), three follow-on
investments in existing direct investments (£9.7 million) and
committed to one secondary investment (£8.8 million).
Direct investments have continued to grow as a
proportion of the portfolio, reaching a portfolio of 30 separate
underlying companies and 22% of portfolio NAV (30 September 2023:
26 separate underlying companies and 19% of portfolio NAV). Direct
investments often do not attract any underlying fees (whereas
private equity funds do) and therefore they have the potential to
act as a tailwind to PPET's performance.
PPET overcommits to funds to ensure the most
efficient use of its resources, optimise returns and to obtain
exposure to the best managers in the mid-market, an approach
employed since inception. Outstanding commitments at the Period-end
amounted to £663.8 million (30 September 2023: £652.0 million) and
are expected to be largely drawn over the next five years. The
value of outstanding commitments in excess of liquid resources as a
percentage of portfolio value (referred to as the 'over-commitment
ratio') was 35.9% at 31 March 2024 (30 September 2023: 35.2%), at
the lower end of the Manager's long-term target range of
30%-75%.
PPET received £61.0 million of distributions
from investments during the Period (31 March 2023: £83.6 million),
a decrease on prior year and a consequence of lower private equity
market activity, particularly in relation to exits. The realised
return from the distributions equated to 2.3 times cost (31 March
2023: 2.6 times). Total drawdowns during the Period fell to £86.9
million (31 March 2023: £104.4 million). Whilst drawdowns were
higher than amounts received as distributions, it is worth noting
that £27.7 million of drawdowns related to new direct investments
and fund secondaries (31 March 2023: £20.6 million), where
deployment is directly under the Manager's control and
discretion.
Liquidity and
Bank Facility
From a balance sheet point of view, PPET remains
in a comfortable position, with cash and cash equivalents of £27.4
million (30 September 2023: £9.4 million) and £163.3 million
remaining undrawn of its £300.0 million revolving credit facility
('RCF') as at 31 March 2024 (30 September 2023: £197.7
million).
Whilst the Company has been more reliant upon
its credit facility during the last six months, this was a
conscious move to further fund and expand its direct investment
book. The direct investment portfolio was introduced in 2019, is
still maturing and to date has required upfront cash investment. As
it reaches a more mature state, it will become a generator of cash
as exits are realised. The Manager believes there will be a number
of exits from the direct investment portfolio over the next 12-24
months, which will provide PPET with the opportunity to reduce
amounts drawn on the RCF should it be deemed appropriate to do
so.
The RCF matures in December 2025, and the Board
continues to monitor the size and terms of PPET's debt
facility.
Dividends
PPET has paid an enhanced quarterly dividend
since 2016, and the Board remains committed to maintaining the
value of the dividend in real terms. The dividend is effectively a
regular return of capital to shareholders at NAV and I am acutely
aware that this is an important feature of PPET for many of its
shareholders.
PPET intends to make a total dividend for the
year to 30 September 2024 of 16.8 pence per share, representing an
increase of 5.0% on the 16.0 pence per share paid for the year to
30 September 2023. PPET has already paid one quarterly dividend of
4.2 pence per share so far this year and the Board has announced a
second interim dividend of 4.2 pence per share which will be paid
on 26 July 2024 to shareholders on the register on 21 June
2024.
Other Corporate
Changes
As I mentioned earlier, PPET changed its name at
the end of April. At that time, our company secretarial contract
was novated from abrdn Holdings Limited to GPMS Corporate Secretary
Limited, an indirect subsidiary of Patria. We also, temporarily,
changed registered office to that of our legal advisers, Dickson
Minto, at 16 Charlotte Square, Edinburgh, EH2 4DF. We plan to align
our registered office with Patria once it has established its
permanent Edinburgh office later this year.
Industry
Activity
The Board monitors industry activity and, in
particular, has closely followed the debate on cost disclosures.
The Board fully supports changes to the current regulatory regime
and believes that PPET is penalised by current regulation. The
inclusion of costs embedded in our underlying investee funds in the
overall PPET costs is misleading to investors. PPET's costs appear
to be prohibitively high which has led to some platforms, most
notably the Fidelity platform, blocking new investors into PPET
shares. The Board has sought to engage with Fidelity on its
rationale for the blocking and no answers have been forthcoming
which is extremely disappointing. The Board takes this very
seriously and is engaged with the wider investment trust industry
to continue to put pressure on the government and regulators to
address the situation. However, in light of the forthcoming UK
General Election, the Board is concerned that any progress made to
date, could be subject to delay.
The Board is also aware of industry concerns
around valuation, and the expected FCA Valuation Review. The Board
engages with the Manager on valuation processes and procedures
regularly. The Board believes the rigorous valuation processes
employed by the Manager, and scrutinised by the Board, ensures that
the PPET published NAV figure is accurate and reflective of the
fair value of the underlying portfolio.
Outlook
Market conditions remain challenging with
continued levels of uncertainty and risk. That said, the Board and
the Manager remain optimistic about the remainder of the year given
the improving signs of sentiment, especially the value creation
activities of Funds to generate both deal opportunities and
distributions. It is evident that Funds are having to think more
clearly about margin expansion to help drive more exits and to
create the value-add necessary to access the estimated $1.2 billion
of dry powder funding that will help drive more exits. Further,
greater clarity on interest rates in both in Europe and US will
improve credit conditions, and allow buyers and sellers to price
assets with greater certainty to further support investor
confidence. Our portfolio holds good quality companies, and
overall, the Board and the Manager believe that PPET is
well-positioned to benefit from improving market conditions
alongside the hands-on portfolio management and value creation
activities of Funds.
As mentioned, PPET's investment objective has
been consistent over the last two decades, being centred on
partnering with a carefully selected group of leading private
equity managers, principally in the European midmarket. I do not
foresee a material change to that going forward, albeit I expect
PPET's focus within the mid-market will continue to evolve more
towards the lower end, i.e. companies with an enterprise value at
entry of between €100m and €500m. We believe that there is an
abundance of attractive private companies in this segment, with
clear value creation opportunities and less reliance on leverage
and IPOs to generate returns.
It also remains my expectation that direct
investments will continue to grow as a proportion of the PPET
portfolio, even with the expectation of liquidity coming from that
part of the portfolio over the coming year. This increase in
exposure should further capture the benefits of their underlying
lower costs compared to Funds. Furthermore, the secondary market in
private equity is becoming larger and more strategically important
with every passing year, and I expect PPET's Manager to continue be
active there, both on the buy and sell-side.
Lastly, the Board will continue to monitor the
evolution of the PPET share price and, in the event of further
sizeable distributions from the portfolio, may look to extend the
current buyback programme. As mentioned, I am encouraged by the
Manager's transition to Patria, and the value that it can
potentially bring to PPET. The Board and I are looking forward to
actively working with both the Manager and the broader Patria team
to drive further value for PPET shareholders.
Alan Devine
Chair,
21 June 2024
INTERIM MANAGEMENT REPORT AND
DIRECTORS' RESPONSIBILITY STATEMENT
PRINCIPAL RISKS
& UNCERTAINITIES
The Board has an ongoing process for
identifying, evaluating and managing the principal risks, emerging
risks and uncertainties of the Company.
The principal risks faced by the Company relate
to the Company's investment activities and are set out in the
Strategic Report contained within the Annual Report for the year
ended 30 September 2023 (the "2023 Annual Report").
They comprise the following risk
categories:
• Market
•
Over-commitment
• Investment
selection
• Climate
• Liquidity
• Credit
•
Operational
The Board continues to closely monitor the
political and economic uncertainties which could affect the global
economy and financial markets, particularly ongoing interest rate
risk in both Europe and the US, and the impact of the forthcoming
UK General Election and US Presidential Election, and French
Parliamentary Election. The Board is also monitoring the potential
for an increase in operational risk following the change of control
of the Company's Manager.
These factors are addressed in the risk
categories set out above and further details on how they are
managed and mitigated are provided in the 2023 Annual Report. The
Board will continue to assess these risks on an ongoing
basis.
In all other respects, the Company's principal
risks, emerging risks and uncertainties have not changed materially
since the date of the 2023 Annual Report.
GOING
CONCERN
In accordance with the Financial Reporting
Council's Guidance on Risk Management, Internal Control and Related
Financial and Business Reporting, the Directors have undertaken a
rigorous review of the Company's ability to continue as a going
concern as a basis for preparing the financial
statements.
The Board has taken into account; the £300.0
million committed, syndicated revolving credit facility which
matures in December 2025; the future cash flow projections,
including the impact of stress testing on the portfolio, the
ongoing expenses forecasts for the financial year, and the
Company's net resources available for investment. The Directors are
also mindful of the principal and emerging risks and uncertainties,
as disclosed.
Having reviewed these matters, the Directors
believe that the Company has adequate financial resources to
continue its operational existence for the foreseeable future and
for at least 12 months from the date of this Half-Yearly Report.
Accordingly, they continue to adopt the going concern basis in
preparing the Half-Yearly Report.
RELATED PARTY
TRANSACTIONS
As noted in the Chair's Statement, the change of
control of the Manager, subsequent to 31 March 2024, has resulted
in changes to the Company's related party transactions. Details of
the Company's parent undertaking and related party transactions are
set out in note 13 to the Financial Statements.
DIRECTORS'
RESPONSIBILITY STATEMENT
The Directors are responsible for preparing the
Half-Yearly Report, in accordance with applicable laws and
regulations. The Directors confirm that, to the best of their
knowledge:
• The condensed set of
financial statements has been prepared in accordance with Financial
Reporting Standard 104 (Interim Financial Reporting) and gives a
true and fair view of the assets, liabilities, financial position
and profit or loss of the Company;
• The Interim
Management Report, together with the Chair's Statement and
Investment Manager's Report, includes a fair review of the
information required by DTR 4.2.7R of the Disclosure Guidance and
Transparency Rules, being an indication of important events that
have occurred during the first six months of the financial year and
their impact on the condensed set of financial statements, and a
description of the principal risks and uncertainties for the
remaining six months of the year; and
• The financial
statements include a fair review of the information required by DTR
4.28R of the Disclosure Guidance and Transparency Rules, being
related party transactions that have taken place in the first six
months of the financial year and that have materially affected the
financial position or performance of the Company during that
period, and any changes in the related party transactions described
in the last Annual Report that could do so.
The Half-Yearly Financial Report was approved by
the Board and the above Directors' Responsibility Statement was
signed on its behalf by the Chair.
For Patria Private Equity Trust plc
Alan Devine
Chair
21 June 2024
INVESTMENT
STRATEGY
PPET's investment objective is to achieve
long-term total returns through holding a diversified portfolio of
private equity funds and direct investments into private companies
alongside private equity managers ('co-investments'), a majority of
which will have a European focus.
INVESTMENT
POLICY
The Company: (i) commits to private equity
funds on a primary basis; (ii) acquires private equity fund
interests in the secondary market; and (iii) makes direct
investments into private companies via co-investments and
single-asset secondaries. Its policy is to maintain a broadly
diversified portfolio by country, industry sector, maturity and
number of underlying investments.
The objective is for the portfolio to comprise
around 50 'active' private equity fund investments; this excludes
funds that have recently been raised, but have not yet started
investing, and funds that are close to or being wound up. The
Company may also invest up to 25% of its assets in direct
investments into private companies, via co-investments and single
asset secondaries alongside private equity managers.
The Company may also hold direct private
equity investments or quoted securities as a result of
distributions in specie from its portfolio of fund investments. The
Company's policy is normally to dispose of such assets where they
are held on an unrestricted basis.
To maximise the proportion of invested assets,
the Company follows an over-commitment strategy by making
commitments which exceed its uninvested capital. In making such
commitments, the Manager, together with the Board, will take into
account the uninvested capital, the value and timing of expected
and projected cashflows to and from the portfolio and, from time to
time, may use borrowings to meet drawdowns. The Board has agreed
that the over-commitment ratio should sit within the range of 30%
to 75% over the long-term.
The Company's maximum borrowing capacity,
defined in its articles of association, is an amount equal to the
aggregate of the amount paid up on the issued share capital of the
Company and the amount standing to the credit of the reserves of
the Company. However, it is expected that borrowings would not
normally exceed 30% of the Company's net assets at the time of
drawdown.
The Company's non-sterling currency exposure
is principally to the euro and US dollar. The Company does not seek
to hedge this exposure into sterling, although any borrowings in
euros and other currencies in which the Company is invested would
have such a hedging effect.
Cash held pending investment is invested in
short-dated government bonds, money-market instruments, bank
deposits or other similar investments. Cash held pending investment
may also be invested in other listed investment companies or
trusts. The Company will not invest more than 15% of its total
assets in such listed equities.
The investment limits described above are all
measured at the time of investment.
PORTFOLIO
CONSTRUCTION AND APPROACH
Investments made by PPET are typically with or
alongside private equity firms with whom the Manager has an
established relationship of more than ten years.
As at 31 March 2024, PPET directly held 83
separate fund investments (30 September 2023: 80) comprising
primary and secondary fund interests, as well as 30 separate direct
investments (30 September 2023: 26).
Through its portfolio of directly held
investments, the Company indirectly has exposure to a diverse range
of underlying portfolio companies, as well as additional underlying
fund of fund and co-investment interests. At 31 March 2024, PPET's
underlying portfolio included exposure to 714 separate underlying
portfolio companies (30 September 2023: 720).
PPET predominantly invests in European
mid-market companies. Around 74% (30 September 2023: 75%) of the
total value of underlying portfolio company exposure1 is
invested in European domiciled operating companies and the Board
expects this to remain the case over the longer term, with a
weighting towards North-Western Europe. This has been PPET's
geographic focus since its inception in 2001 and where it has a
strong, long-term track record.
However, PPET also selectively seeks exposure to
North American mid-market companies, as a means to access emerging
growth or investment trends that cannot be fully captured by
investing in Europe alone.
PPET has a well-balanced portfolio in terms of
non-cyclical and cyclical exposure. Currently the largest single
sector exposure, Information Technology, represents 22% of the
total value of underlying portfolio company exposure1
(30 September 2023: 22%) and it is expected that no single sector
will be more than 30% of the portfolio over the longer term. Over
time, the Manager anticipates a continuation of the recent shift
toward sectors that are experiencing long-term growth (such as
Technology and Healthcare) at the expense of more cyclical sectors,
such as Industrial and Consumer Discretionary.
Environmental, Social and Governance ('ESG') is
a strategic priority for the Board and the Manager. PPET aims to be
an active, long-term responsible investor and ESG is a fundamental
component of PPET's investment process. Further detail on the
Manager's approach to ESG can be found in the Annual Report to 30
September 2023.
1 Excludes underlying fund and
co-investments indirectly held through the Company
portfolio.
INTRODUCTION TO
THE MANAGER - HOW WE INVEST
In order to achieve the investment objective,
maintain a balanced portfolio and take advantage of opportunities
as they arise, PPET invests in three types of private equity
investment:
1. Primary
Funds
PPET commits to investing in a new private
equity fund. The committed capital will generally be drawn over a
three- to five year period as investments in underlying private
companies are made. Proceeds are then returned to PPET when the
underlying companies are sold, typically over a four- to five-year
holding period.
Primary investment has been the core focus of
PPET's investment objective since its inception in 2001. Primary
investments can provide PPET with:
• consistent exposure
to leading private equity managers;
• underlying portfolio
diversification;
• a steady,
predictable cash flow profile; and
• help drive PPET's
dealflow in secondaries and direct investments.
2. Fund
Secondaries
PPET acquires a single fund interest or a
portfolio of fund interests from another investor, with the prior
approval of the private equity managers of the target funds. PPET
pays the seller a cash amount for the interests and takes on any
outstanding commitments to the target funds.
Typically this would occur at a point where
the target fund (or funds) has already invested the majority of its
capital and so the Manager is able to evaluate the quality of the
underlying portfolio of companies prior to investment. The price
paid in this type of transaction will reflect the age profile of
the funds, the quality of the managers and the quality of the
underlying portfolios, therefore can often be at a premium or
discount to NAV. Fund secondaries allow the Manager to gain
exposure to funds of new or existing managers a later stage in a
fund's life.
Secondaries typically have a shorter
investment duration than a primary investment. Fund secondaries are
opportunistic in nature and their availability is dependent on
multiple market and deal-specific factors.
3. Direct
Investments
PPET makes direct investments into private
companies alongside other private equity managers, either through a
co-investment or a single asset secondary transaction.
Co-investment was introduced to the investment objective in
2019.
PPET's strategy is to only directly invest
alongside private equity managers with which Patria Private Equity
has made a primary fund investment. The Manager is seeking to build
a diversified portfolio of around 30 to 35 direct investments in
order to mitigate concentration risk.
INVESTMENT
MANAGER'S REVIEW
Performance
The Manager is delighted by PPET's strong
performance during the period, in what remains a challenging
market. The key driver of that performance has been underlying
earnings growth and, in that respect, it is worth reiterating that
the vast majority of PPET's underlying portfolio of private
companies are growing, profitable and, importantly, cash
generative. Many of these businesses are niche market leaders
providing mission critical services and in less cyclical sectors
such as Technology, Healthcare, Consumer Staples and Business
Services.
The NAV Total Return ('NAV TR') for the six
months ended 31 March 2024 was 2.0% versus 6.9% for the FTSE
All-Share Index. The valuation of the portfolio at 31 March 2024
increased 4.4% over the period on a constant currency basis,
partially offset by a 1.9% decrease attributable to FX on the
portfolio, principally due to the appreciation of pound sterling
compared to US dollar and the Euro. The increase in value of the
portfolio on a per share basis was 20.3p. This was principally made
up of unrealised and realised gains and income of 36p, partially
offset by FX, dividends and costs associated with management fee,
administrative and financing of 30.5p.
The unrealised gains in the period are
attributable to the strong performance of the underlying portfolio,
which continues to perform well operationally. Looking at the top
50 underlying portfolio companies, which are the main value drivers
and equate to 38.2% of the portfolio, the average revenue and
EBITDA growth was 12.4% and 22.4% respectively in the twelve months
to 31 March 2024. That has helped drive the resilient valuation
performance in the portfolio. Focusing on the same cohort of top
companies, the median valuation multiple was14.4x EBITDA at 31
March 2024, compared with 14.0x at 30 September 2023. We are
especially pleased about progress in PPET's co-investment
portfolio, which has seen a constant currency valuation uplift of
8.9% during the six months to 31 March 2024.
Realised gains were derived from full or partial
sales of underlying portfolio companies during the six-month
period, which were at an average uplift of 27.3% to the unrealised
value two quarters prior (31 March 2023: 15.1%). The headline
realised return from the portfolio exits equated to 2.3 times cost,
which we consider a strong performance in what was a challenging
backdrop for private equity managers to conduct successful exit
processes.
NAV
Performance
|
Pence per share
|
NAV as at 1 October 2023
|
777.7
|
Net realised gains and income from
portfolio
|
+22.7
|
Net unrealised gains at constant FX on
portfolio
|
+13.4
|
Net unrealised FX losses on portfolio
|
-15.7
|
Dividends paid
|
-8.0
|
Management fee, administration and finance
costs
|
-6.8
|
Accretion from share buy-back scheme
|
+0.7
|
Net income for other assets
|
1.0
|
NAV as at 31 March 2024
|
784.9
|
Top companies
|
% of portfolio
|
Median valuation
multiple
|
Media leverage
multiple
|
Average LTM Revenue
growth
|
Average LTM EBITDA
growth
|
10
|
13.6%
|
14.7x
|
4.2x
|
14.9%
|
23.4%
|
30
|
28.9%
|
14.9x
|
4.8x
|
12.5%
|
20.2%
|
50
|
38.2%
|
14.4x
|
3.9x
|
12.4%
|
22.4%
|
Drawdowns
|
Amount - £million
|
EDG (Co-investment)
|
7.0
|
IK Partnership II
|
6.3
|
IK IX Luxco 15 S.a.r.l.
(Co-investment)
|
5.2
|
Procemsa (Co-investment)
|
4.5
|
Altor V
|
4.4
|
Nordic Capital Evolution Fund
|
4.2
|
One Peak Co-invest III LP
(Co-investment)
|
4.2
|
Chanelle Pharma (Co-investment)
|
3.4
|
IK IX
|
2.9
|
Advent X
|
2.9
|
Other
|
41.9
|
£86.9 million was drawn down during the period
(31 March 2023: £104.4 million), primarily for investment into
existing and new underlying portfolio companies. £57.1 million of
this figure related to primary fund drawdowns (31 March 2023: £83.8
million), with the remainder related to direct investments and fund
secondaries, which is fully under the control of the Manager and as
planned. Direct investment and fund secondaries are covered in
detail later in the review.
Fund drawdowns have fallen materially compared
to prior year due to the lower level of private equity M&A
activity in recent months. Drawdowns during the period were mainly
used to fund new investments, with notably large drawdowns relating
to the following underlying portfolio companies:
· Valoria Capital
(IK Partnership Fund II) - French independent financial advisor
with over €4.0bn AuM;
· Medica Group (IK
Fund IX) - UK healthcare services provider focused on teleradiology
and imaging services;
· Arterex
(Investindustrial Growth III) - Medical device contract
manufacturing platform;
· Autocirc (Nordic
Evolution Fund I) - Recycled automotive spare parts;
· FLSmidth (Altor
Fund V) - Services and equipment for mining and cement
industries.
Private equity funds usually have credit
facilities to finance new investments initially before drawing the
capital from investors. We estimate that PPET had around £93.6
million held on these underlying fund credit facilities at 31 March
2024 (30 September 2023: £79.5 million), and we expect that this
will be largely drawn over the next 12 months.
Distributions
|
Amount - £million
|
IK VIII
|
12.9
|
Investindustrial Growth
|
6.0
|
Advent International Global Private Equity
VIII
|
5.3
|
CVC VII
|
5.0
|
Exponent III
|
4.1
|
Other
|
27.7
|
|
|
£61.0 million of distributions were received
from funds during the year (31 March 2023: £83.6 million). This
decrease in distributions was expected by the Manager and is a
direct consequence of the lower levels of private equity M&A
activity during the period.
Exit activity continues to be driven by market
appetite for high quality private companies in resilient sectors,
which often have the potential to expand inorganically through
add-on acquisitions. These resilient businesses continue to attract
interest from both trade and financial buyers.
Initial Public Offering ('IPO') activity in the
portfolio remained relatively low, albeit there was at least some
activity during the period, following no activity in 2023. Douglas
(a beauty products retailer) and RENK Group (a manufacturer of
gearboxes) both successfully listed on the Frankfurt Stock Exchange
during the early part of 2024.
The largest distributions during the period
related to the following underlying portfolio companies, with the
relevant funds stated in brackets:
· Nomios (IK Fund
VIII) - a European provider of cybersecurity and secure networking
services;
· Aspia (IK Fund
VIII) - a provider of accounting, payroll and skilled advisory
services in Sweden;
· Messer Industries
(CVC VII) - a leading European supplier of industrial gases used
across multiple industries;
· Procemsa
(Investindustrial Growth Fund I) - pharmaceutical CDMO provider of
food supplements and vitamins;
· Meadow Foods
(Exponent Fund III) - UK B2B provider of dairy foods and related
ingredients
Commitments
PPET made new commitments totalling £108.2
million during the period (31 March 2023: £140.8 million), with
three new primary fund commitments (£63.9 million), four new direct
investments (£25.7 million), three follow-on investments in
existing direct investments (£9.7 million) and one secondary
investment (£8.8 million) during the period. Outstanding
commitments at the period-end amounted to £663.8 million (31 March
2023: £699.7 million).
The value of outstanding commitments in excess
of liquid resources as a percentage of portfolio value (referred to
as the 'over-commitment ratio') was 35.9% at 31 March 2024 (31
March 2023: 37.6%). This is broadly in line with the figure twelve
months prior and is at the lower end of our long-term target range
of 30%-75%. We estimate that £91.9 million of the reported
outstanding commitments are unlikely to be drawn down (31 March
2023: £72.0 million), due to the nature of private equity
investing, with private equity funds not always being fully
drawn.
Outstanding
Commitments
As
at
|
Outstanding
Commitments
|
Outstanding
commitments in excess of undrawn loan facility and case resources
as a % of portfolio NAV (£million)
|
30 September 2020
|
30.9%
|
471.4
|
30 September 2021
|
32.5%
|
557.1
|
30 September 2022
|
42.8%
|
678.9
|
30 September 2023
|
35.2%
|
652.0
|
31 March 2024
|
35.9%
|
663.8
|
Outstanding
Commitment Movement between 1 October 2023 and 31 March
2024
|
£million
|
Outstanding commitments as at 1 October
2023
|
652.0
|
Fund investment drawdowns
|
-59.3
|
Co-investment and secondary funding
|
-27.7
|
New commitments
|
+108.2
|
Recallable distributions
|
+3.1
|
Foreign exchange impact
|
-12.5
|
Outstanding commitments as at 31 March
2024
|
663.8
|
Balance Sheet
and Liquidity
The balance sheet remains in a strong position
with cash and cash equivalents at 31 March 2024 of £27.4 million
(30 September 2023: £9.4) and £163.3 million remaining undrawn of
its £300.0 million revolving credit facility (30 September 2023:
£197.7 million), totalling £190.7 million of available
resources.
As discussed earlier by the Chair, PPET has
drawn more of its credit facility during the last six months. This
decision was taken by the Manager in order for PPET to further
expand its direct investment book, during a period of lower
distributions from fund investments. We believe that there will be
a number of exits from the direct investment portfolio over the
next 12-24 months, which would result in the reduction of amounts
drawn on the RCF should it be deemed appropriate to do
so.
Investment
Activity
Primary Funds
£63.9 million was committed to three new primary
funds during the first six months of the year (31 March 2023:
£121.3 million into five new primary funds). As a reminder, PPET's
primary fund strategy is to partner with private equity firms,
principally in the Europe, that have genuine sector expertise and
operational value creation capabilities with a core mid-market
buyout orientation, i.e. focusing on businesses with an enterprise
value between €100.0 million and €1.0 billion at entry. The firms
that PPET has partnered with during the period fulfil this criteria
and all comprise established relationships that the Manager has
developed over many years, often decades.
Investment
|
|
£m
|
Description
|
IK Fund X
|
|
26.1
|
Focused primarily on lower middle
market businesses in Northern Continental Europe across Business
Services, Consumer/Food, Healthcare and Industrials.
|
Bowmark Fund
VII
|
|
25.0
|
Focused on mid-market businesses in
the UK software and services sectors.
|
Altor Climate Transition Fund
I
|
|
12.8
|
Focused on investments across
Northern Europe that will help to decarbonise industries with a
traditionally heavy carbon footprint.
|
Case study - Primary Funds -
Bowmark Capital
Bowmark is a leading lower mid-market
private equity firm in the UK, with a proven strategy and long
track record in highly attractive sectors.
Investment: Bowmark
Capital Partners VII
Fund
size: £907m
PPET
comment: £25m
Commitment year:
2024
Geographic focus: UK
Target company size: Mid-market
Sectors: Data and Insight,
Managed IT Services, Software and Tech-Enabled Business
Services
Investment strategy: Growth
Buyout
Overview
• Bowmark is an
established, high-quality UK GP and a brand name in the market. It
was originally founded in 1997 as Sagitta Private Equity, part of
the Sagitta Group, but was renamed Bowmark following a management
buyout completed by Kevin Grassby and Charles Ind in
2004.
• Bowmark targets
investments in high quality, market leading businesses with the
opportunity for transformational growth, driven by structural
rather than cyclical trends. These companies are typically
technology or tech-enabled B2B services companies, often with
disruptive business models in traditional markets, and have high
recurring revenue, strong sales and earnings growth, and strong
cash generation.
• Bowmark partners with
high quality management teams to accelerate growth, with the aim of
doubling earnings during its ownership to generate attractive, and
consistent, returns.
PPET's Exposure
• PPET's commitment to Bowmark VII is its first with Bowmark, as
part of the Trust's strategic evolution to target a number of high
quality, lower mid-market managers.
• The Patria Private Equity team has known Bowmark for two
decades and been an investor in Bowmark since 2004.
Direct investments
During the six-month period, PPET invested and
committed £34.4 million four new direct investments and three
follow-on investments in existing direct investments (31 March
2023: £14.9 million into two new co-investments and two follow-on
investments).
The level of deployment into new direct
investments has increased in the period to 31 March 2024 compared
to prior year. This has been due to the Manager seeing a greater
number of high-quality direct investment leads compared to prior
year.
As a reminder, co-investments (which comprise
the majority of the direct investment portfolio, along with
single-asset secondaries) were introduced to PPET's investment
objective in 2019 and bring a number of advantages, most notably
greater control over portfolio construction and lower associated
costs (and therefore higher return potential). Over the longer term
the Manager expects direct investments to equate to around 25-30%
of the portfolio.
At 31 March 2024 there were 30 direct
investments in PPET's portfolio, equating to 22% of portfolio NAV.
The direct investment portfolio is slowly maturing, with an average
investment age of 2.1 years at 31 March 2024, and we are delighted
with its performance so far, with only one investment held below
cost and several direct investments ahead of their initial
investment case. We believe that there are a number of candidates
for exit over the next 12-24 months, which will return material
cash back to PPET.
Investment
|
|
£m
|
Description
|
European Digital
Group
|
|
8.9
|
Business
services provider focused on digital transformation. Investment
alongside Latour Capital. See case study.
|
Procemsa
|
|
7.3
|
Italian-headquartered vitamins and food supplements Contact
Development and Manufacturing Organisation ('CDMO'). Investment
alongside Investindustrial.
|
Goodlife
|
|
5.2
|
Manufacturer of frozen snacks in Europe, with a diversified
business mix across Retail, Out-of-Home and Industry. Investment
alongside IK Partners.
|
Follow-on investment into
Visma
|
|
4.7
|
Provider
of cloud-based, mission critical business software. Investment
alongside Hg.
|
Channelle
Pharma
|
|
4.3
|
Manufacturer of generic animal and human health products
headquartered in Ireland. Investment alongside Exponent.
|
Follow-on investment into an
undisclosed company
|
|
4.2
|
European-headquartered technology business in the healthcare
sector, the details of which are undisclosed due to confidentiality
restrictions.
|
Follow-on investment into an
undisclosed company
|
|
0.8
|
US-headquartered consumer business, the details of which
remain
undisclosed due to confidentiality restrictions.
|
Case Study - Co-investment -
European Digital Group
EDG (European Digital Group) is an
integrated B2B services provider in the digital transformation and
digital marketing segments based in France.
Lead
Manager: Latour
Capital/Montefiore
PPET's investment:
€10.5m
Investment year:
2024
Geographic focus:
France
Size
at entry: Mid-market (<€1bn
EV)
Sector: Business
services
Company Overview
• EDG is the largest
French digitally native, integrated Business Services provider in
the digital transformation and digital marketing
segments.
• EDG helps businesses
transform digitally. It is an end to end, one stop shop for its
clients with 5 complementary business units: Data and AI,
Technology and Cybersecurity, Performance Marketing, Digital
Content and Growth Enablers.
• 95% of the firm's
revenue is generated in France from a diversified client base with
no dependence on any one sector.
• The platform has had an
impressive M&A journey to date completing 23 acquisitions,
which all benefit from cost and cross sell synergies once
integrated into the wider EDG platform, enhancing growth at a
subsidiary level.
• The group is led by a
well-respected, serial entrepreneur and the team comprises 1,500
staff. All subsidiary managers are investors in EDG and
incentivised at their subsidiary level.
The
Opportunity
• Operates in a resilient,
highly fragmented market where growth is driven by continuing
digitalisation of companies and the continued shortage of tech
talent.
• Differentiated market
positioning as a digital native local specialist with an end to end
offering and clear value proposition at competitive pricing,
particularly for the small and mid-sized enterprise, an area
underserved by global players.
• Impressive growth since
inception, materially outperforming the market with acquired
businesses growing well above historic rates due to the benefits of
being part of the group.
• Diversified business
model which leverages a 'snowball effect' as it scales to deliver
strong synergies which has been supplemented by M&A with over
20 acquisitions to date.
• Clear value creation
plan with multiple levers including further initiatives to drive
organic growth in each business unit as well as through synergies,
M&A and potential new product launches.
• Highly rated founder and
management team with an entrepreneurial approach, able to unlock
attractive acquisition targets and drive best in class talent
retention rates in a highly competitive market.
• Attractive timing to
acquire a resilient asset alongside two high quality sponsors
(Latour and Montefiore) with in-depth knowledge of the
business.
Fund
Secondaries
PPET committed £8.8 million into a new secondary
investment during the period (31 March 2023: £4.6 million into one
new secondary investment), which was funded in April
2024.
Investment
|
|
£m
|
Description
|
Clean
Biologics
|
|
8.8
|
Contract
Testing Development and Manufacturing (CDTMO) business. See Case
Study
|
Case Study - Fund Secondaries-
Clean Biologics
Clean Biologics is a leading
European Contract Testing, Development and Manufacturing (CTDMO)
business.
Lead
Manager: ArchiMed
PPET's investment:
€10.4m
Investment year:
2024
Geographic focus: France/North
America
Size
at entry: Lower mid-market
(<€500m EV)
Sector: Healthcare
Company Overview
• Clean Biologics is a
Contract Testing Development and Manufacturing (CDTMO) business
providing industry-compliant services for pharmaceutical and
biopharmaceutical companies, specialising in the safety and
production of biopharmaceuticals for clinical trials.
• The Group was formed
following ArchiMed's acquisition of Clean Cells in 2018, a QC
testing business, and the subsequent acquisitions of Biodextris and
Naobios, which expanded the business' core competencies and
bolstered its CDMO capabilities.
• Clean Biologics was held
in ArchiMed's second fund, MED II, and, over the hold period of 5
years, it significantly outperformed its original business plan.
During this time, the business tripled its revenue and EBITDA.
Through engagement with their MedTalent network and discussions
with trade buyers, ArchiMed identified a number of further value
creation opportunities for the business and elected to roll the
business into a continuation vehicle.
The
Opportunity
• Clearly defined strategy
focused around changing the organisational structure of the
business. Through engagement with a number of trade buyers,
ArchiMed concluded that exit optionality and value would be
maximised by splitting Clean Biologics into two distinct businesses
focused on drug quality control testing and CDMO services,
respectively.
• Large market (c. $5.4bn)
experiencing favourable commercial and regulatory tailwinds for
structural growth (13% CAGR expected) driven by increased biopharma
spending on clinical trials and R&D and increased regulatory
scrutiny supporting QC testing.
• Clean Biologics is a
scarce asset with Clean Cells being one of the few reaming
independent QC testing providers having differentiated scientific
capabilities (in traditional as well as Next Generation Sequencing
based QC testing services) and Biodextris having differentiated
expertise in production of niche therapeutic proteins.
• Attractive investment
timing, benefiting from recent capex and improving market
sentiment/forward pipeline visibility. The investment coincided
with early shoots of recovery in global biopharma spending on
clinical trials, after a challenging period, with the companies
positioned to benefit from the historical investment in significant
capacity expansion (3-4x) of facilities.
• Opportunity to back
ArchiMed, a high conviction manager, on a transaction in their
sector sweet spot where they have significant experience, track
record of returns and strong trade buyer relationships.
Portfolio
Construction
The underlying portfolio consists of 714 private
companies (30 September 2023: 720), largely within the European
midmarket and spread across different countries, sectors and
vintages. At 31 March 2024, 12 (30 September 2023: 12) companies
equated to more than 1% of portfolio NAV based on underlying
portfolio company exposure, with the largest single exposure being
PPET's investment in Action, equating to 2.0%.
Geographic Exposure1
The portfolio is well diversified, which means
that there isn't a reliance on one private equity manager, company,
geographic region, sector or vintage to drive performance. At 31
March 2024, 74% of underlying private companies were headquartered
in Europe. PPET's underlying portfolio remains largely oriented to
Northwestern Europe, with only 10% (30 September 2023: 10%) of
underlying portfolio company exposure in Southern Europe and
Eastern Europe. PPET is well diversified by region across
Northwestern Europe, with the Nordics being the highest exposure at
15% (30 September 2023: 14%).
North America equates to 24% (30 September 2023:
24%) of the total, with exposure to the region obtained through
European private equity managers that have expanded their
operations into North America and US-headquartered lower mid-market
private equity managers that PPET partners with for specific sector
exposure (e.g. Great Hill Partners in Technology, American
Industrial Partners in Industrials, Windrose in Healthcare and
Seidler in Consumer).
Geography of
the Underlying Portfolio as at 31 March 2024
|
Exposure %
|
North America
|
24
|
Nordics
|
15
|
United Kingdom
|
15
|
France
|
13
|
Germany
|
12
|
Benelux
|
7
|
Spain
|
4
|
Italy
|
3
|
Switzerland
|
2
|
Other ex-Europe
|
2
|
1 Based on the latest available
information from underlying managers. Figures represent percentage
of total value of underlying portfolio company exposure. Geographic
exposure is defined as the geographic region where underlying
portfolio companies are headquartered.
Sector
Exposure1
At 31 March 2024, Technology and Healthcare
represented a combined 41% of the underlying portfolio company
exposure 30 September 2023: 41%. When combined with Consumer
Staples, these more stable, less cyclical sectors equate to over
half of PPET's underlying portfolio at 51% (30 September 2023:
51%). It is worth noting that PPET generally invests in Technology
businesses that are profitable and Business-to-Business ('B2B')
focused and therefore has relatively low exposure to higher growth,
unprofitable technology businesses where the consumer is the
customer.
The other half of the portfolio is exposed to
more cyclical sectors, notably Industrials, Consumer Discretionary
and Financials. That said, there are sub-sectors within these areas
that provide growth opportunities, such as Fintech, Business
Services and industrial sub-sectors related to the 'green
transition'. These businesses often have a valuable product or an
essential service offering with a strong digital component. Some
examples within our top 20 underlying portfolio companies by value
include European Camping Group, CFC Underwriting (cyber security
insurance MGA), Trioplast (sustainable manufacturer of polyethylene
film) and Planet (provider of payments solutions for hospitality
and retail).
|
% Exposure as at
|
Sector
|
|
31 March 2024
|
Information
Technology
|
|
22
|
Healthcare
|
|
19
|
Industrial
|
|
19
|
Consumer
discretionary
|
|
14
|
Consumer
staples
|
|
10
|
Financials
|
|
9
|
Materials
|
|
4
|
Energy
|
|
1
|
Utilities
|
|
1
|
Telecommunication
services
|
|
1
|
1 Based on
the latest available information from underlying managers. Figures
represent percentage of total value of underlying portfolio company
exposure.
Maturity
Analysis1,2
The Manager does not try to time the market with
respect to PPET, instead aiming for consistent exposure across
recent vintage years. Therefore, there is an even split of
portfolio companies at the underlying level that are approaching
maturity (held for more than four years) and companies typically
still in the value creation phase (held for less than 4 years).
With 50% being in vintages of four years or more 30 September 2023:
49%, this should underpin exit activity and distributions once
private equity market activity increases again.
Holding
Period
|
%
|
1 year
|
9
|
2 years
|
18
|
3 years
|
23
|
4 years
|
12
|
5 years
|
13
|
>5 years
|
25
|
1 Based on
the latest available information from underlying managers. Figures
represent percentage of total value of underlying portfolio company
exposure.
2 The
holding period is the length of time that an underlying portfolio
company has been held since its initial investment date by the
Company.
Outlook
The acquisition by Patria has brought renewed
energy and certainty to PPET's investment management team, but
importantly will not result in any change in PPET's investment
strategy. Therefore, our focus remains principally on the European
mid-market, and we continue to partner with a small group of
leading private equity managers, that we believe are
differentiated, specialist and can bring significant value to the
businesses they invest in.
In line with the current strategic plan, we will
continue to look to increase the proportion of direct investments
in the PPET portfolio, alongside our core managers, which will
reduce the underlying fees PPET pays and should provide a further
enhancement in performance. The secondary market remains highly
relevant to our approach, both from a buying and selling
perspective. We are currently seeing better pricing for high
quality assets in the secondary market and we may look to
opportunistically realise some older, non-core positions to provide
additional firepower for new investments.
Private equity market sentiment appears to have
improved in 2024 compared to 2023, but we haven't yet seen this
translate into a material pick-up in signed transactions and,
importantly, exits. We have seen some notable deals being announced
in the European market over 2024 (e.g. Alter Domus, Audiotonix,
Dorna, Eres Group) and several more rumoured. Furthermore, we have
seen European PE-backed IPOs return in the form of Douglas, Renk
and Galderma, in addition to the listing of CVC, a leading private
equity firm, in Amsterdam.
The existing portfolio continues to perform
resiliently and remains well positioned for a pick-up in activity
levels. Any uptick should result in an increase in distributions to
PPET and should be a tailwind to NAV growth, given PE assets tend
to trade at an uplift to their last bottom-up valuation.
That said, we continue to believe that PPET's
balance sheet is in a good place and can withstand a prolonged
period of lower activity should financial markets remain
subdued.
Alan Gauld,
Lead Investment Manager
For Patria Capital Partners LLP
21 June 2024
TEN LARGEST
INVESTMENTS
at 31 March 2024
1
|
|
CVC
Capital Partners
|
|
Undertakes
medium and large sized buyout transactions across a range of
industries and geographies
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fund Size:
€16.4bn
Strategy: Mid to large buyouts
EV of investments: €500m-€5bn
Geography: Europe and North America
Website: www.cvc.com
|
|
CVC Capital Partners
VII
|
31/03/24
|
30/09/23
|
|
|
Value
(£'000)
|
42,531
|
44,945
|
|
|
Cost
(£'000)
|
24,598
|
24,898
|
3.4% of NAV
(30 September 2023:
3.8%)
|
|
|
Commitment
(€'000)
|
35,000
|
35,000
|
|
|
Amount
Funded
|
100.1%
|
97.2%
|
|
|
Income
(£'000)*
|
2
|
1,945
|
|
|
|
|
|
|
|
|
|
|
|
2
|
|
Nordic Capital
|
|
Invests in
medium- to large-sized buyout deals in Northern Europe, through
five dedicated sector teams, with the ability to invest in
healthcare on a global basis.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fund size:
€4.3bn
Strategy: Mid to large buyouts
EV of investments: €200m-€800m
Geography: Northern Europe (Global in
Healthcare)
Website: www.nordiccapital.com
|
|
Nordic Capital Fund
IX
|
31/03/24
|
30/09/23
|
|
|
Value
(£'000)
|
38,565
|
37,762
|
|
|
Cost
(£'000)
|
23,403
|
23,403
|
3.1% of NAV (30 September
2023: 3.2%)
|
|
|
Commitment
(€'000)
|
30,000
|
30,000
|
|
|
Amount
Funded
|
106.8%
|
100.0%
|
|
|
Income
(£'000)*
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
3
|
|
Altor
|
|
Focuses on
investing in and developing medium-sized companies with a Nordic
origin that offer potential for value creation through revenue
growth, margin expansion, improved capital management and strategic
re-positioning.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fund Size:
€2.1bn
Strategy: Mid-market buyouts
EV of investments: €50m-€500m
Geography: Northern
Europe
Website: www.altor.com
|
|
Altor Fund
IV
|
31/03/24
|
30/09/23
|
|
|
Value
(£'000)
|
37,476
|
34,954
|
|
|
Cost
(£'000)
|
30,405
|
29,206
|
3.0% of NAV (30 September
2023: 2.9%)
|
|
|
Commitment
(€'000)
|
55,000
|
55,000
|
|
|
Amount
Funded
|
78.7%
|
76.0%
|
|
|
Income
(£'000)*
|
300
|
-
|
|
|
|
|
|
|
|
|
|
|
|
4
|
|
Structured Solutions IV Primary Holdings
|
|
A
diversified secondary transaction comprising large cap buyout funds
in Europe and the US.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fund Size:
$125m
Strategy: Various
EV of investments: $500m-$5bn
Geography: Europe and North
America
Website: n/a
|
|
Structured Solutions IV
Primary Holdings
|
31/03/24
|
30/09/23
|
|
|
Value
(£'000)
|
35,908
|
36,687
|
|
|
Cost
(£'000)
|
30,760
|
31,066
|
2.9% of NAV (30 September
2023: 3.1%)
|
|
|
Commitment
(€'000)
|
62,500
|
62,500
|
|
|
Amount
Funded
|
72.6%
|
72.0%
|
|
|
Income
(£'000)*
|
-
|
886
|
|
|
|
|
|
|
|
|
|
|
|
5
|
|
Bridgepoint
|
|
A leading
mid-market focused private equity firm targeting buyout investments
in European companies with strong market positions and earnings
growth potential across six core sectors.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fund Size:
€5.8bn
Strategy: Mid-market buyouts
EV of investments: €200m -
€1bn
Geography: Europe
Website:
www.bridgepoint.eu
|
|
Bridgepoint Europe
VI
|
31/03/24
|
30/09/23
|
|
|
Value
(£'000)
|
34,873
|
34,488
|
|
|
Cost
(£'000)
|
23,614
|
23,707
|
2.8% of NAV (30 September
2023: 2.9%)
|
|
|
Commitment
($'000)
|
30,000
|
30,000
|
|
|
Amount
Funded
|
95.9%
|
94.4%
|
|
|
Income
(£'000)
|
-
|
222
|
|
|
|
|
|
|
|
|
|
|
|
6
|
|
Advent International
|
|
Invests in
attractive niches within Business and Financial Services,
Healthcare, Industrial, Retail and Technology sectors.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fund Size:
€13.0bn
Strategy: Mid to large buyouts
EV of investments: $200m-$3bn
Geography: Global with a focus on Europe and North
America
Website: www.adventinternational.com
|
|
Advent International Global
Private Equity VIII
|
31/03/24
|
30/09/23
|
|
|
Value
(£'000)
|
33,886
|
45,051
|
|
|
Cost
(£'000)
|
26,091
|
27,671
|
2.7% of NAV (30 September
2023: 3.8%)
|
|
|
Commitment
(€'000)
|
45,000
|
45,000
|
|
|
Amount
Funded
|
100.0%
|
100.0%
|
|
|
Income
(£'000)*
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
7
|
|
Altor
|
|
Focuses on
investing in and developing medium-sized companies often with a
Nordic origin and sustainability angle, that offer potential for
value creation through revenue growth, margin expansion, improved
capital management and strategic re-positioning.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fund Size:
€2.6bn
Strategy:
Mid-market buyouts
EV of
investments: €150-€1bn
Geography:
Northern Europe
Website:
www.altor.com
|
|
Altor Fund
V
|
31/03/24
|
30/09/23
|
|
|
Value
(£'000)
|
32,092
|
26,706
|
|
|
Cost
(£'000)
|
27,478
|
23,069
|
2.6% of NAV (30 September
2023: 2.2%)
|
|
|
Commitment
(€'000)
|
43,000
|
43,000
|
|
|
Amount
Funded
|
65.2%
|
53.4%
|
|
|
Income
(£'000)*
|
55
|
238
|
|
|
|
|
|
|
|
|
|
|
|
8
|
|
PAI
|
|
Targets
upper mid-market businesses in Western Europe, with a particular
focus on continental Europe. Typically invests in market leaders
across Food and Consumer Goods, Healthcare, Business Services, and
Industrials sectors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fund Size:
€5.1bn
Strategy: Upper Mid-market buyouts
EV of investments: €300m -
€1.2bn
Geography: Western Europe
Website:
www.paipartners.com
|
|
PAI Europe
VII
|
31/03/24
|
30/09/23
|
|
|
Value
(£'000)
|
30,099
|
29,681
|
|
|
Cost
(£'000)
|
23,054
|
22,789
|
2.4% of NAV (30 September
2023: 2.5%)
|
|
|
Commitment
($'000)
|
30,000
|
30,000
|
|
|
Amount
Funded
|
87.6%
|
86.5%
|
|
|
Income
(£'000)
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
9
|
|
Advent International
|
|
Targets
high growth, international expansion and strategic restructuring
opportunities in five core sectors: Business and Financial
Services; Healthcare; Industrial and Energy; Retail, Consumer and
Leisure; and Technology.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fund Size:
$17.5bn
Strategy: Mid to large buyouts
EV of investments: $200m-$3bn
Geography: Primarily Europe and North America
Website: www.adventinternational.com
|
|
Advent International Global
Private Equity IX
|
31/03/24
|
30/09/23
|
|
|
Value
(£'000)
|
28,670
|
27,262
|
|
|
Cost
(£'000)
|
19,794
|
19,794
|
2.3% of NAV (30 September
2023: 2.3%)
|
|
|
Commitment
(€'000)
|
25,000
|
25,000
|
|
|
Amount
Funded
|
94.1%
|
94.1%
|
|
|
Income
(£'000)*
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
10
|
|
Action
|
|
Since its
establishment in 1993, Benelux-based Action has grown into the
leading non-food discount retailer in the region with more than
2,300 stores and close to
80,000
employees.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fund
Size: €2.5bn
Strategy: Consumer staples
Year of
investment: 2020
Private Equity
Manager: 3i group plc
Investment:
co-investment
Geography: Europe and North
America
Website:
www.action.nl
|
|
3i 2020 Co-investment 1
SCSp
|
31/03/24
|
30/09/24
|
|
|
Value
(£'000)
|
27,733
|
26,160
|
|
|
Cost
(£'000)
|
6,380
|
6,380
|
2.2% of NAV (30 September
2023: 2.2%)
|
|
|
Commitment
($'000)
|
7,939
|
7,939
|
|
|
Amount
Funded
|
100.0%
|
100.0%
|
|
|
Income
(£'000)*
|
2,211
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes:
|
|
|
|
|
|
|
|
|
|
|
* Performance
information has been prepared by PPET and has not been approved by
the General Partners of the funds or any of their Associates.
Income figures are for the six months to 31 March 2024 and 31 March
2023 respectively.
The Company's position in Action is
held through 3i 2020 Co-investment 1 SCSp (formerly known as 3i
Venice SCSp, a special purpose vehicle managed by 3i as
co-investment lead.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
INVESTMENT PORTFOLIO
at 31 March 2024
Vintage
|
Investment
|
Number of
investments
|
Outstanding commitments
£'000*
|
Cost
£'000
|
Valuation
£'0001
|
Net
multiple2
|
% of NAV
|
2017
|
CVC Capital
Partners VII
|
31
|
1,665
|
24,598
|
42,531
|
1.9x
|
3.5
|
2018
|
Nordic
Capital Fund IX
|
13
|
7,681
|
23,403
|
38,565
|
1.7x
|
3.2
|
2014
|
Altor Fund
IV
|
16
|
10,047
|
30,405
|
37,476
|
1.8x
|
3.1
|
2021
|
Structured
Solutions IV Primary Holdings*
|
53
|
13,559
|
30,760
|
35,908
|
1.3x
|
3.0
|
2018
|
Bridgepoint
Europe VI
|
17
|
1,060
|
23,614
|
134,873
|
1.5x
|
2.9
|
2016
|
Advent
International Global Private Equity VIII
|
27
|
0
|
26,091
|
33,886
|
1.9x
|
2.8
|
2019
|
Altor Fund
V
|
36
|
9,530
|
27,478
|
32,092
|
1.3x
|
2.7
|
2018
|
PAI Europe
VII
|
18
|
4,976
|
23,054
|
30,099
|
1.5x
|
2.5
|
2019
|
Advent
International Global Private Equity IX
|
37
|
1,273
|
19,794
|
28,670
|
1.5x
|
2.4
|
2020
|
3i 2020
Co-investment 1 SCSp3
|
1
|
0
|
6,380
|
27,733
|
4.7x
|
2.3
|
2015
|
Exponent
Private Equity Partners III, LP.
|
10
|
3,052
|
19,591
|
26,203
|
1.9x
|
2.2
|
2019
|
Triton Fund
V*
|
19
|
9,731
|
16,122
|
25,749
|
1.5x
|
2.1
|
2017
|
HgCapital
8
|
8
|
2,442
|
6,253
|
25,597
|
2.9x
|
2.1
|
2016
|
Sixth
Cinven Fund
|
14
|
2,520
|
15,554
|
24,822
|
1.9x
|
2.1
|
2020
|
IK
IX
|
14
|
877
|
20,584
|
24,260
|
1.2x
|
2.0
|
2021
|
IK
Partnership II
|
5
|
597
|
21,083
|
24,260
|
1.2x
|
2.0
|
2020
|
Cinven
7
|
17
|
2,023
|
19,469
|
23,403
|
1.3x
|
1.9
|
2020
|
Nordic
Capital X
|
16
|
3,790
|
17,753
|
23,403
|
1.3x
|
1.9
|
2016
|
IK Fund
VIII
|
16
|
2,091
|
13,113
|
23,320
|
1.9x
|
1.9
|
2014
|
CVC
VI
|
22
|
1,635
|
14,187
|
22,905
|
2.2x
|
1.9
|
2020
|
Investindustrial VII
|
12
|
7,043
|
14,988
|
22,591
|
1.5x
|
1.9
|
2019
|
MSouth Equity Partners IV
|
13
|
1,407
|
15,598
|
22,073
|
1.4x
|
1.8
|
2020
|
Vitruvian
IV
|
28
|
2,519
|
18,747
|
22,020
|
1.2x
|
1.8
|
2019
|
American
Industrial Partners VII
|
15
|
2,930
|
14,771
|
20,472
|
1.5x
|
1.7
|
2020
|
Capiton
VI
|
10
|
6,522
|
10,589
|
18,641
|
1.8x
|
1.5
|
2020
|
MPI-COI-NAMSA SLP3
|
1
|
1,856
|
5,573
|
18,439
|
2.8x
|
1.5
|
2021
|
Arbor
Co-Investment LP3
|
1
|
0
|
8,374
|
17,011
|
2.0x
|
1.4
|
2014
|
Permira
V
|
8
|
719
|
8,467
|
16,125
|
3.5x
|
1.3
|
2013
|
TowerBrook
Investors IV
|
18
|
10,230
|
12,233
|
15,901
|
2.2x
|
1.3
|
2014
|
PAI Europe
VI
|
12
|
1,581
|
9,310
|
15,857
|
1.9x
|
1.3
|
2022
|
Uvesco
Co-invest3
|
1
|
2,178
|
6,268
|
15,122
|
2.2x
|
1.3
|
2015
|
Bridgepoint
Europe V
|
9
|
2,483
|
12,123
|
14,571
|
2.0x
|
1.2
|
2021
|
Capiton VI
Wundex Co-Investment3
|
1
|
3,150
|
5,378
|
14,526
|
2.7x
|
1.2
|
2021
|
ECG
Co-invest SLP*,3
|
1
|
-
3
|
6,920
|
14,479
|
2.1x
|
1.2
|
2021
|
Excellere
Partners Fund IV
|
4
|
15,225
|
12,684
|
14,303
|
1.1x
|
1.2
|
2020
|
Hg Genesis
9
|
12
|
3,086
|
9,773
|
13,586
|
1.3x
|
1.1
|
2015
|
Equistone
Partners Europe Fund V
|
10
|
1,639
|
16,842
|
13,363
|
1.6x
|
1.1
|
2020
|
Seidler
Equity Partners VII L.P.
|
7
|
1,075
|
13,048
|
13,284
|
1.1x
|
1.1
|
2020
|
PAI
Mid-Market I
|
7
|
10,134
|
11,280
|
13,281
|
1.2x
|
1.1
|
2019
|
PAI
Strategic Partnerships SCSp
|
2
|
119
|
6,659
|
13,251
|
2.0x
|
1.1
|
2020
|
Hg Saturn
2
|
7
|
3,012
|
8,947
|
13,113
|
1.4x
|
1.1
|
2021
|
Advent
Technology II-A
|
11
|
14,587
|
10,648
|
13,018
|
1.2x
|
1.1
|
2020
|
Triton
Smaller Mid-Cap Fund II*
|
8
|
10,190
|
11,163
|
12,969
|
1.2x
|
1.1
|
2013
|
Nordic
Capital VIII
|
22
|
2,753
|
17,719
|
11,928
|
1.5x
|
1.0
|
2021
|
MI NGE
S.L.P.3
|
1
|
825
|
8,153
|
11,450
|
1.4x
|
1.0
|
2022
|
Advent
International Global Private Equity X
|
13
|
15,006
|
10,840
|
11,389
|
1.1x
|
0.9
|
2021
|
Hg Isaac
Co-Invest LP3
|
1
|
40
|
7,571
|
11,180
|
1.5x
|
0.9
|
2019
|
Great Hill
Partners VII
|
18
|
328
|
8,213
|
11,130
|
1.5x
|
0.9
|
2020
|
Hg Mercury
3
|
11
|
3,133
|
7,489
|
10,850
|
1.4x
|
0.9
|
2021
|
MPI-COI-PROLLENIUM SLP3
|
1
|
1,395
|
7,147
|
10,563
|
1.5x
|
0.9
|
2019
|
Vitruvian I
CF LP
|
8
|
7,782
|
7,227
|
10,186
|
1.3x
|
0.8
|
2021
|
Eurazeo
Payment Luxembourg Fund SCSp3
|
1
|
1,074
|
7,798
|
10,008
|
1.3x
|
0.8
|
2021
|
Nordic
Capital Evolution Fund
|
8
|
16,872
|
8,899
|
10,007
|
1.1x
|
0.8
|
2017
|
Onex
Partners IV LP
|
7
|
568
|
10,228
|
9,775
|
1.4x
|
0.8
|
2022
|
Hg Saturn
3
|
2
|
18,665
|
9,161
|
9,548
|
1.0x
|
0.8
|
2021
|
IK
Co-invest Questel3
|
1
|
0
|
8,658
|
9,366
|
1.1x
|
0.8
|
2023
|
One Peak
Co-invest III LP3
|
1
|
0
|
9,434
|
9,257
|
1.0x
|
0.8
|
2020
|
Vitruvian
III
|
26
|
1,020
|
5,112
|
8,845
|
2.2x
|
0.7
|
2016
|
Astorg
VI
|
5
|
1,570
|
205
|
8,776
|
1.7x
|
0.7
|
2021
|
VIP SIV I
LP3
|
1
|
3,330
|
5,670
|
8,562
|
1.5x
|
0.7
|
2023
|
Maguar
Continuation Fund I GmbH & Co. KG3
|
1
|
930
|
6,767
|
8,209
|
1.2x
|
0.7
|
2021
|
WindRose
Health Investors Fund VI
|
6
|
9,052
|
7,222
|
8,145
|
1.1x
|
0.7
|
2020
|
Hg Vardos
Co-invest L.P.3
|
1
|
0
|
4,244
|
8,021
|
1.9x
|
0.7
|
2021
|
CDL
Coinvestment SPV3
|
1
|
0
|
5,294
|
7,666
|
1.4x
|
0.6
|
2021
|
Hg Riley
Co-Invest LP3
|
1
|
0
|
6,836
|
7,382
|
1.1x
|
0.6
|
2021
|
Bengal
Co-Invest SCSp3
|
1
|
2,436
|
6,198
|
7,304
|
1.2x
|
0.6
|
2021
|
MPI-COI-SUAN SLP3
|
1
|
37
|
6,402
|
7,210
|
1.1x
|
0.6
|
2024
|
Latour
Co-Invest EDG3
|
1
|
2,022
|
6,963
|
6,946
|
1.0x
|
0.6
|
2021
|
Latour
Co-invest Funecap*,3
|
1
|
0
|
4,287
|
6,801
|
1.4x
|
0.6
|
2018
|
Investindustrial Growth
|
3
|
5,831
|
9,559
|
6,700
|
2.3x
|
0.6
|
2021
|
Permira
Growth Opportunities II
|
11
|
19,093
|
9,594
|
6,693
|
0.7x
|
0.6
|
2023
|
Procemsa
Build-Up SCSp3
|
1
|
2,760
|
4,530
|
6,470
|
1.4x
|
0.5
|
2023
|
IK IX Luxco
15 S.a.r.l.3
|
1
|
0
|
5,247
|
6,254
|
1.2x
|
0.5
|
2019
|
Alphaone
International S.à.r.l.3
|
1
|
1,693
|
3,522
|
6,091
|
1.7x
|
0.5
|
2021
|
bd-capital
Partners Chase3
|
1
|
0
|
4,291
|
6,028
|
1.4x
|
0.5
|
2023
|
Capiton
Quantum GmbH & Co
|
2
|
720
|
3,857
|
5,642
|
1.5x
|
0.5
|
2015
|
Nordic
Capital VII
|
8
|
1,513
|
10,486
|
5,297
|
1.4x
|
0.4
|
2022
|
Leviathan
Holdings, L.P.3
|
1
|
0
|
4,866
|
5,281
|
1.1x
|
0.4
|
2022
|
Hg Genesis
10
|
2
|
20,853
|
4,835
|
5,072
|
1.0x
|
0.4
|
2021
|
Nordic
Capital WH1 Beta, L.P.3
|
1
|
387
|
3,308
|
4,299
|
1.2x
|
0.4
|
2022
|
Nordic
Capital Fund XI
|
6
|
20,669
|
4,979
|
4,244
|
0.9x
|
0.4
|
2012
|
Equistone
Partners Europe Fund IV
|
6
|
485
|
8,762
|
4,000
|
2.1x
|
0.3
|
2021
|
ASI Omega
Holdco Limited3
|
1
|
17
|
4,259
|
3,977
|
0.9x
|
0.3
|
2022
|
ArchiMed -
Med Platform 2
|
3
|
21,248
|
4,298
|
3,879
|
0.9x
|
0.3
|
2022
|
Investindustrial Growth III
|
2
|
21,795
|
3,905
|
3,554
|
0.9x
|
0.3
|
2024
|
Exponent
Herriot Co-Investment Partners, LP3
|
1
|
830
|
3,444
|
3,441
|
1.0x
|
0.3
|
2021
|
ArchiMed
III
|
5
|
9,128
|
3,756
|
3,340
|
0.9x
|
0.3
|
2023
|
Latour
Co-invest Funecap II*,3
|
1
|
0
|
2,952
|
2,856
|
1.0x
|
0.2
|
2022
|
AV Invest
B3*,3
|
1
|
211
|
4,887
|
2,842
|
0.6x
|
0.2
|
2015
|
Capiton
V
|
9
|
161
|
7,324
|
2,810
|
0.8x
|
0.2
|
2022
|
One Peak
Growth III
|
6
|
9,667
|
3,201
|
2,739
|
0.9x
|
0.2
|
2021
|
Great Hill
Equity Partners VIII
|
5
|
12,302
|
3,585
|
2,733
|
0.8x
|
0.2
|
2022
|
Altor Fund
VI
|
6
|
23,510
|
2,129
|
2,595
|
1.2x
|
0.2
|
2023
|
ECG 2
Co-Invest S.L.P.*,3
|
1
|
513
|
2,132
|
2,493
|
1.2x
|
0.2
|
2012
|
Advent
International Global Private Equity VII
|
18
|
811
|
4,957
|
2,187
|
2.1x
|
0.2
|
2001
|
CVC
III*
|
1
|
412
|
4,110
|
1,894
|
2.7x
|
0.2
|
2012
|
IK Fund
VII
|
6
|
1,707
|
5,871
|
1,842
|
2.0x
|
0.2
|
2013
|
Bridgepoint
Europe IV
|
4
|
773
|
2,900
|
1,676
|
1.6x
|
0.1
|
2011
|
Montagu
IV
|
4
|
657
|
4,771
|
1,452
|
1.8x
|
0.1
|
2022
|
PAI Europe
VIII
|
7
|
23,676
|
1,955
|
1,415
|
0.7x
|
0.1
|
2022
|
American
Industrial Partners V
|
6
|
32
|
1,327
|
1,356
|
1.4x
|
0.1
|
2023
|
Vitruvian
V
|
2
|
23,755
|
1,876
|
1,241
|
0.7x
|
0.1
|
2008
|
CVC
V*
|
1
|
426
|
4,310
|
852
|
2.4x
|
0.1
|
2019
|
Gilde
Buy-Out Fund IV
|
1
|
0
|
2,262
|
497
|
1.2x
|
0.0
|
2006
|
3i Eurofund
V
|
0
|
0
|
9,282
|
369
|
2.7x
|
0.0
|
2023
|
Montefiore
Investment VI
|
1
|
16,571
|
515
|
175
|
0.3x
|
0.0
|
2007
|
Industri
Kapital 2007 Fund
|
0
|
1,483
|
5,545
|
93
|
1.4x
|
0.0
|
2023
|
Montefiore
Expansion I
|
0
|
8,285
|
258
|
92
|
0.0x
|
0.0
|
2023
|
Latour
Capital IV
|
1
|
24,933
|
715
|
62
|
0.1x
|
0.0
|
2024
|
Altor ACT I
(No. 1) AB
|
0
|
12,597
|
215
|
35
|
0.2x
|
0.0
|
2023
|
Hg Mercury
4
|
1
|
25,341
|
288
|
-
|
0.0x
|
0.0
|
2023
|
Seidler
Equity Partners VIII, L.P.
|
0
|
15,594
|
247
|
-
|
0.0x
|
0.0
|
2023
|
IK X
Fund
|
0
|
25,625
|
-
|
-
|
n/a
|
0.0
|
2024
|
Bowmark
Capital Partners VII, L.P.
|
0
|
25,000
|
-
|
-
|
n/a
|
0.0
|
2024
|
MED BIO
FPCI
|
0
|
8,883
|
-
|
-
|
n/a
|
0.0
|
2024
|
Hg Vega
Co-Invest L.P.3
|
0
|
4,749
|
-
|
-
|
n/a
|
0.0
|
|
|
|
|
|
|
|
|
|
Total
investments5
|
867
|
663,768
|
1,018,518
|
1,319,063
|
|
109.0
|
|
Non-portfolio assets less
liabilities
|
|
|
|
(115,352)
|
|
(9.0)
|
|
Total shareholders'
funds
|
|
|
|
1,203,711
|
|
100.0
|
|
|
|
|
|
|
|
|
1. All funds are valued by the
manager of the relevant fund or co-investment as at 31 March 2024,
with the exception of those funds suffixed with an * which were
valued as at 31 December 2023 or initial funding amount
paid.
2. The net multiple has been
calculated by the Manager in sterling on the basis of the total
realised and unrealised return for the interest held in each fund
and co‑investments.
These figures have not been reviewed or approved by the relevant
fund or its manager.
3. Co-investment position.
4. New commitment for which an
underlying company has yet to be acquired.
5. The 867 underlying investments
represent holdings in 714 separate underlying private companies, 44
underlying fund investments and 9 underlying
co-investments.
CONDENSED
STATEMENT OF COMPREHENSIVE INCOME (UNAUDITED)
For the six
months ended 31 March 2024
|
|
For the six months ended 31
March 2024
|
For the six months ended 31
March 2023
|
|
Notes
|
Revenue
|
Capital
|
Total
|
Revenue
|
Capital
|
Total
|
|
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
Total capital gains on
investments
|
|
-
|
27,134
|
27,134
|
-
|
37,688
|
37,688
|
Currency
gains / (losses)
|
|
-
|
1,241
|
1,241
|
-
|
(396)
|
(396)
|
Income
|
4
|
5,001
|
-
|
5,001
|
6,357
|
-
|
6,357
|
Investment
management fee
|
5
|
(286)
|
(5,424)
|
(5,710)
|
(278)
|
(5,291)
|
(5,569)
|
Administrative expenses
|
|
(641)
|
-
|
(641)
|
(568)
|
-
|
(568)
|
Profit before finance costs
and taxation
|
|
4,074
|
22,951
|
27,025
|
5,511
|
32,001
|
37,512
|
Finance
costs
|
|
(218)
|
(3,800)
|
(4,018)
|
(136)
|
(2,411)
|
(2,547)
|
Profit before
taxation
|
|
3,856
|
19,151
|
23,007
|
5,375
|
29,590
|
34,965
|
Taxation
|
7
|
(707)
|
31
|
(676)
|
(911)
|
373
|
(538)
|
Profit after
taxation
|
|
3,149
|
19,182
|
22,331
|
|
4,464
|
29,963
|
Earnings per share - basic
and diluted
|
7
|
2.05p
|
12.51p
|
14.56p
|
|
2.90p
|
19.49p
|
|
|
|
|
|
|
|
|
The Total
columns of this statement represents the profit and loss account of
the Company.
|
There are
no items of other comprehensive income, therefore this statement is
the single statement of comprehensive income of the
Company.
|
All revenue
and capital items in the above statement are derived from
continuing operations.
|
No
operations were acquired or discontinued in the period.
|
CONDENSED STATEMENT OF FINANCIAL
POSITION (UNAUDITED)
As at 31 March
2024
|
|
As at
|
As at
|
|
|
31 March
2024
|
30 September
2023
|
|
Notes
|
£'000
|
£'000
|
£'000
|
£'000
|
Non-current
assets
|
|
|
|
|
|
Investments
|
8
|
|
1,319,063
|
|
1,261,995
|
|
|
|
1,319,063
|
|
1,261,995
|
Current
assets
|
|
|
|
|
|
Receivables
|
|
156
|
|
30,117
|
|
Cash and
cash equivalents
|
|
27,444
|
|
9,436
|
|
Total current
assets
|
|
27,600
|
|
39,553
|
|
|
|
|
|
|
|
Creditors: amounts falling
due within one year
|
|
|
|
|
|
Payables
|
|
(7,432)
|
|
(5,022)
|
|
Revolving
credit facility
|
10
|
(135,520)
|
|
(100,883)
|
|
Net current
liabilities
|
|
|
(115,352)
|
|
(66,352)
|
|
|
|
|
|
|
Total assets less current
liabilities
|
|
|
1,203,711
|
|
1,195,643
|
|
|
|
|
|
|
Capital and
reserves
|
|
|
|
|
|
Called-up
share capital
|
|
|
307
|
|
307
|
Share
premium account
|
|
|
86,485
|
|
86,485
|
Special
reserve
|
|
|
51,503
|
|
51,503
|
Capital
redemption reserve
|
|
|
94
|
|
94
|
Capital
reserves
|
|
|
1,065,322
|
|
1,057,254
|
Revenue
reserve
|
|
|
-
|
|
-
|
Total shareholders'
funds
|
|
|
1,203,711
|
|
1,195,643
|
|
|
|
|
|
|
Net asset value per equity
share
|
9
|
|
784.9p
|
|
777.7p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The
Financial Statements of Patria Private Equity Opportunities Trust
plc (formerly known as abrdn Private Equity Opportunities Trust
plc), registered number SC216638 were approved and authorised for
issue by the Board of Directors on 21 June 2024 and were signed on
its behalf by Alan Devine,
Chair.
|
CONDENSED
STATEMENT OF CHANGES IN EQUITY (UNAUDITED)
For the six months ended 31
March 2024
|
|
|
Called-up
|
Share
|
|
Capital
|
|
|
|
|
|
share
|
premium
|
Special
|
redemption
|
Capital
|
Revenue
|
|
|
|
capital
|
account
|
reserve
|
reserve
|
reserves
|
reserve
|
Total
|
|
Notes
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
Balance at 1 October
2023
|
|
307
|
86,485
|
51,503
|
94
|
1,057,254
|
-
|
1,195,643
|
Profit
after taxation
|
|
-
|
-
|
-
|
-
|
19,182
|
3,149
|
22,331
|
Dividends
paid
|
6
|
-
|
-
|
-
|
-
|
(9,150)
|
(3,149)
|
(12,299)
|
Repurchase
of shares into treasury
|
|
-
|
-
|
-
|
-
|
(1,964)
|
-
|
(1,964)
|
Balance at 31 March
2024
|
|
307
|
86,485
|
51,503
|
94
|
1,065,322
|
-
|
1,203,711
|
|
|
|
|
|
|
|
|
|
For the six months ended 31
March 2023
|
|
|
|
|
|
|
|
|
Called-up
|
Share
|
|
Capital
|
|
|
|
|
|
share
|
premium
|
Special
|
redemption
|
Capital
|
Revenue
|
|
|
|
capital
|
account
|
reserve
|
reserve
|
reserves
|
reserve
|
Total
|
|
Notes
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
Balance at 1 October
2022
|
|
307
|
86,485
|
51,503
|
94
|
1,019,663
|
-
|
1,158,052
|
Profit
after taxation
|
|
-
|
-
|
-
|
-
|
29,963
|
4,464
|
34,427
|
Dividends
paid
|
6
|
-
|
-
|
-
|
-
|
(6,605)
|
(4,464)
|
(11,069)
|
Balance at 31 March
2023
|
|
307
|
86,485
|
51,503
|
94
|
1,043,021
|
-
|
1,181,410
|
CONDENSED
STATEMENT OF CASH FLOWS (UNAUDITED)
|
|
|
|
|
|
For the six
months
|
For the six
months
|
|
|
ended 31 March
2024
|
ended 31 March
2023
|
|
Notes
|
£'000
|
£'000
|
£'000
|
£'000
|
Cashflows from operating
activities
|
|
|
|
|
|
Profit
before taxation
|
|
|
23,007
|
|
34,965
|
Adjusted
for:
|
|
|
|
|
|
Finance
costs
|
|
|
4,018
|
|
2,547
|
Gains on
disposal of investments
|
8
|
|
(30,876)
|
|
(39,321)
|
Revaluation
of investments
|
|
|
3,653
|
|
1,430
|
Unrealised
currency (gains) / losses on non-investments
|
|
|
(932)
|
|
396
|
Decrease /
(increase) in debtors
|
|
|
234
|
|
(51)
|
Increase in
creditors
|
|
|
2,412
|
|
193
|
Tax
deducted from non-UK income
|
|
|
(676)
|
|
(538)
|
Net cash inflow / (outflow)
from operating activities
|
|
|
840
|
|
(379)
|
|
|
|
|
|
|
Investing
activities
|
|
|
|
|
|
Purchase of
investments
|
8
|
(86,940)
|
|
(100,594)
|
|
Purchase of
secondary investments
|
|
-
|
|
(3,857)
|
|
Distributions of capital proceeds received by
investments
|
8
|
57,095
|
|
78,064
|
|
Net
distributions receivable from investments
|
|
-
|
|
249
|
|
Receipt of
proceeds from disposal of investments
|
|
30,040
|
|
-
|
|
Net cash outflow from
investing activities
|
|
|
195
|
|
(26,138)
|
|
|
|
|
|
|
Financing
activities
|
|
|
|
|
|
Revolving
credit facility - amounts drawn
|
|
53,215
|
|
30,813
|
|
Revolving
credit facility - amounts repaid
|
|
(17,729)
|
|
-
|
|
Interest
paid and arrangement fees
|
|
(4,000)
|
|
(3,273)
|
|
Ordinary
dividends paid
|
6
|
(12,299)
|
|
(11,069)
|
|
Repurchase
of shares into treasury
|
9
|
(1,964)
|
-
|
-
|
-
|
Net cash inflow from
financing activities
|
|
|
17,223
|
|
16,471
|
|
|
|
|
|
|
Net increase / (decrease) in
cash and cash equivalents
|
|
|
18,258
|
|
(10,046)
|
|
|
|
|
|
|
Cash and
cash equivalents at the beginning of the period
|
|
|
9,436
|
|
30,341
|
Currency
gains / (losses) on cash and cash equivalents
|
|
|
(250)
|
|
(396)
|
Cash and cash equivalents at
the end of the period
|
|
|
27,444
|
|
19,899
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
consist of:
|
|
|
|
|
|
Cash
|
|
|
27,444
|
|
19,899
|
Cash and cash
equivalents
|
|
|
27,444
|
|
19,899
|
|
|
|
|
|
|
Included in
profit before taxation is dividends received from investments of
£3,733,000 (2023: £3,139,000), interest received from investments
of £918,000 (2023: £2,937,000) and interest received from cash
balances.
|
|
NOTES TO THE
FINANCIAL STATEMENTS
1 Financial
Information
|
The financial information for the
year ended 30 September 2023 within the report is considered
non-statutory as defined in sections 434-436 of the Companies Act
2006. The financial information for the six months ended 31 March
2024 and 31 March 2023 has not been audited. The financial
information for the year ended 30 September 2023 has been extracted
from the published accounts that have been delivered to the
Registrar of Companies and on which the report of the auditor was
unqualified under section 498 of the Companies Act
2006.
|
|
2. Basis of preparation and
going concern
|
The condensed financial statements
for the six months ended 31 March 2024 have been prepared in
accordance with Financial Reporting Standard 104 (Interim Financial
Reporting) and with the Statement of Recommended Practice for
'Financial Statements of Investment Trust Companies and Venture
Capital
Trusts'.
The condensed financial statements
for the six months ended 31 March 2024 have been prepared using the
same accounting policies as the preceding annual financial
statements. This is available at www.patriaprivateequitytrust.com
or on request from the Company Secretary.
The Board have made an assessment of
the Company's ability to continue as a going concern and are
satisfied that the Company has the resources to continue in
business for a period of at least 12 months from the date of these
condensed financial statements. In preparing these condensed
financial statements, the Board have considered:
· the
remaining undrawn balance of the £300.0 million committed,
syndicated revolving credit facility with a maturity date in
December 2025;
· the
level of cash balances. The Manager regularly monitors the
Company's cash position to ensure sufficient cash is held to meet
liabilities as they fall due;
· the
future cash flow projections (including the level of expected
realisation proceeds, the expected future profile of investment
commitments and the terms of the revolving credit facility);
and
· the
Company's cash flows during the period.
Based on a review of the above, the
Directors are satisfied that the Company has, and will maintain,
sufficient resources to continue to meet its liabilities as they
fall due for at least 12 months from the date of approval of the
condensed financial statements. Accordingly, the condensed
financial statements have been prepared on a going concern
basis.
|
|
3. Exchange
rates
|
Rates of
exchange to sterling were:
|
|
|
|
As at 31 March
2024
|
As at 30 September
2023
|
Euro
|
1.1708
|
1.1528
|
US
Dollar
|
1.2633
|
1.2206
|
Canadian
Dollar
|
1.7108
|
1.6502
|
|
|
Six months
ended
|
Six months
ended
|
|
|
31 March
2024
|
31 March
2023
|
4.
|
Income
|
£'000
|
£'000
|
|
Income from
investments
|
3,734
|
3,139
|
|
Interest
from investments
|
918
|
2,937
|
|
Interest
from cash balances
|
349
|
281
|
|
Total
income
|
5,001
|
6,357
|
|
|
Six months ended 31 March
2024
|
Six months ended 31 March
2023
|
|
|
Revenue
|
Capital
|
Total
|
Revenue
|
Capital
|
Total
|
5
|
Investment management
fees
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
|
|
|
|
|
|
|
|
|
Investment management
fee
|
286
|
5,424
|
5,710
|
278
|
5,291
|
5,569
|
|
|
|
|
|
|
|
|
|
The Manager of the Company is Patria
Capital Partners LLP (formerly known as abrdn Capital Partners
LLP). In order to comply with the Alternative Investment Fund
Managers Directive, the Company appointed Patria Capital Partners
LLP as its Alternative Investment Fund Manager from 1 July
2014.
|
|
|
|
|
|
|
|
|
|
The investment management fee payable
to the Manager is 0.95% per annum of the NAV of the Company. The
investment management fee is allocated 95% to the realised capital
reserve - gains/(losses) on disposal and 5% to the revenue account.
The management agreement between the Company and the Manager is
terminable by either party on twelve months written
notice.
|
|
|
|
Investment management fees due to the
Manager as at 31 March 2024 amounted to £6,448,000 (30 September
2023: £3,943,000).
|
|
|
6 Dividend on ordinary
shares
|
For the financial period ending 31
March 2024, the first interim dividend of 4.20p per ordinary share
was paid on 26 April 2024 (2023: dividend of 4.0p was paid on 21
April 2023). A second interim dividend of 4.20p per share is due to
be paid on 26 July 2024 (2023: dividend of 4.0p was paid on 28 July
2023).
In respect of the year ended 30
September 2023, the third interim dividend of 4.0p per ordinary
share was paid on 27 October 2023 (2022: dividend of 3.6p per
ordinary share paid on 28 October 2022). The fourth interim
dividend of 4.0p per ordinary share was then paid on 26 January
2024 (2023: dividend of 3.6p per ordinary share paid on 27 January
2023).
|
|
|
Six months
ended
|
Six months
ended
|
|
|
31 March
2024
|
31 March
2023
|
7
|
Earnings per share - basic
and diluted
|
p
|
£'000
|
p
|
£'000
|
|
The net return per ordinary
share is based on the following figures:
|
|
|
|
|
|
Revenue net
return
|
2.05
|
3,149
|
2.90
|
4,464
|
|
Capital net
return
|
12.51
|
19,182
|
19.49
|
29,963
|
|
Total net
return
|
14.56
|
22,331
|
22.39
|
34,427
|
|
|
|
|
|
|
|
Weighted
average number of ordinary shares in issue:
|
|
153,746,294
|
|
153,746,294
|
|
|
|
|
|
|
|
There are
no diluting elements to the earnings per share calculation in the
six months ended 31 March 2024 (2023: none).
|
8
|
Investments
|
Six months
ended 31 March
2024
Unquoted
Investments
|
Year ended
30 September 2023 Unquoted
Investments
|
|
|
£'000
|
£'000
|
|
Fair value through profit or
loss:
|
|
|
|
Opening
market value
|
1,261,995
|
1,192,380
|
|
Opening
investment holding gains
|
(304,198)
|
(346,062)
|
|
Opening book
cost
|
957,797
|
846,318
|
|
|
|
|
|
Movements in the
period/year:
|
|
|
|
Additions
at cost
|
86,940
|
189,446
|
|
Secondary
purchases
|
-
|
3,857
|
|
Distribution of capital proceeds
|
(57,095)
|
(141,555)
|
|
Secondary
sales
|
-
|
(52,995)
|
|
|
987,642
|
845,071
|
|
Gains on
disposal of underlying investments
|
30,876
|
112,726
|
|
Closing book
cost
|
1,018,518
|
957,797
|
|
Closing
investment holding gains
|
300,545
|
304,198
|
|
Closing market
value
|
1,319,063
|
1,261,995
|
|
|
|
|
|
The total
capital gain on investments of £27,134,000 (2023: £37,688,000) per
the Condensed Statement of Comprehensive Income for the six months
ended 31 March 2024 also includes transaction costs of £114,000
(2023: £204,000).
|
9
|
Net asset value per equity
share
|
As at 31 March
2024
|
As at 31 March
2023
|
|
Basic and
diluted:
|
|
|
|
Ordinary
shareholders' funds
|
£1,203,710,699
|
£1,195,643,000
|
|
Number of
ordinary shares in issue
|
153,746,294
|
153,746,294
|
|
Number of
shares excluding those held in treasury
|
153,360,803
|
153,746,294
|
|
Net asset
value per ordinary share
|
784.9p
|
777.7p
|
|
|
|
|
|
The net asset value per ordinary
share and the ordinary shareholders' funds are calculated in
accordance with the Company's articles of association.
|
|
There are no diluting elements to the
net asset value per equity share calculation in the six months
ended 31 March 2024 (2023: none).
The Company repurchased 385,491
(2023: none) of its own ordinary shares during the six months ended
31 March 2024 which are held in treasury.
|
10
|
Revolving credit
facility
|
As at 31 March
2024
|
As at 30 September
2023
|
|
|
£'000
|
£'000
|
|
Revolving
credit facility
|
135,520
|
100,883
|
|
|
|
|
|
At 31 March 2024, the Company had a
£300.0 million committed, multicurrency syndicated revolving credit
facility, of which £136.7 million (30 September 2023: £102.4
million) had been drawn down. The faciltiy is provided by The Royal
Bank of Scotland International Limited, Société Générale and State
Street Bank International GmbH. The facility expires in December
2025.
The interest rate on the facility is calculated as the defined
reference rate of the currency drawn plus 1.625% rising to 2.0%
depending on the level of utlisation, whilst the commitment fee
rate payable on non-utilisation is between 0.7% and 0.8% per annum
based on the level of facility utilisation.
Inclusive of the revolving credit facility balance is £1,135,000 of
unamortised revolving credit facility fees which partially offsets
the total amount of the facility balance drawn as at 31 March 2024
(2023: £1,475,000).
|
11
|
Commitments and contingent
liabilities
|
As at 31 March
2024
|
As at 30 September
2023
|
|
|
£'000
|
£'000
|
|
Outstanding calls on
investments
|
663,768
|
651,991
|
|
|
|
|
|
This
represents commitments made to fund and co-investment interests
remaining undrawn.
|
12. Fair Value
hierarchy
|
FRS 104 requires an entity to
classify fair value measurements using a fair value hierarchy that
reflects the significance of the inputs used in making the
measurements. The fair value hierarchy has the following
classifications:
• Level 1: The unadjusted quoted price in an active market for
identical assets or liabilities that the entity can access at the
measurement date.
• Level 2: Inputs other than quoted prices included within Level
1 that are observable (i.e., developed using market data) for the
asset or liability, either directly or indirectly.
• Level 3: Inputs are unobservable (i.e., for which market data
is unavailable) for the asset or liability.
The Company's financial assets and
liabilities, measured at fair value in the Condensed Statement of
Financial Position, are grouped into the following fair value
hierarchy at 31 March 2024:
|
|
Financial assets at fair
value through profit or loss
|
Level 1
£'000
|
Level 2
£'000
|
Level 3
£'000
|
Total
£'000
|
|
Unquoted
investments
|
-
|
-
|
1,319,063
|
1,319,063
|
|
Net fair value
|
-
|
-
|
1,319,063
|
1,319,063
|
|
|
|
|
|
|
|
As at 30
September 2023::
|
|
|
|
|
|
Financial assets at fair
value through profit or loss
|
Level 1
£'000
|
Level 2
£'000
|
Level
3
£'000
|
Total
£'000
|
|
Unquoted
investments
|
-
|
-
|
1,261,995
|
1,261,995
|
|
Net fair
value
|
-
|
-
|
1,261,995
|
1,261,995
|
Unquoted Investments
Unquoted investments are stated at
the directors' estimate of fair value and follow the
recommendations of the EVCA and the BVCA (European Private Equity
& Venture Capital Association and British Private Equity &
Venture Capital Association). The estimate of fair value is
normally the latest valuation placed on an investment by its
manager as at the Condensed Statement of Financial Position date.
The valuation policies used by the manager in undertaking that
valuation will generally be in line with the joint publication from
the EVCA and the BVCA, 'International Private Equity and Venture
Capital Valuation guidelines'. Fair value can be calculated by the
manager of the investment in a number of ways. In general, the
managers with whom the Company invests adopt a valuation approach
which applies an appropriate comparable listed company multiple to
a private company's earnings or by reference to recent
transactions. Where formal valuations are not completed as at the
Condensed Statement of Financial Position date, the last available
valuation from the manager is adjusted for any subsequent cash
flows occurring between the valuation date and the Condensed
Statement of Financial Position date. The Company's Manager may
further adjust such valuations to reflect any changes in
circumstances from the last manager's formal valuation date to
arrive at the estimate of fair value.
|
13. Parent undertaking and
related party transactions
|
The ultimate parent undertaking of
the Company is Phoenix Group Holdings. The results of the Company
are incorporated into the group financial statements of Phoenix
Group Holdings, which will be available to download from the
website www.thephoenixgroup.com.
Phoenix Life Limited ('PLL', which is
100% owned by Phoenix Group Holdings), and the Company have entered
into a relationship agreement which provides that, for so long as
PLL and its Associates exercise, or control the exercise, of 30% or
more of the voting rights of the Company, PLL and its Associates,
will not seek to enter into any transaction or arrangement with the
Company which is not conducted at arm's length and on normal
commercial terms, take any action that would have the effect of
preventing the Company from carrying on an independent business as
its main activity or from complying with its obligations under the
Listing Rules or propose or procure the proposal of any shareholder
resolution which is intended or appears to be intended to
circumvent the proper application of the Listing Rules. During the
year ended 31 March 2024, PLL received dividends from the Company
totalling £6,590,000
(31 March 2023:
£5,931,000).
During the period ended 31 March 2024
the Manager charged management fees totalling £5,710,000 (31 March
2023: £5,569,000) to the Company in the normal course of business.
The balance of management fees outstanding at 31 March 2024 was
£6,448,000 (30 September 2023: £3,943,000).
abrdn Investment Management Limited,
which shared the same ultimate parent as the Manager during the
period ended 31 March 2024, received fees for the provision of
promotional activities of £30,000 (31 March 2023: £29,000) during
the period. The balance of promotional fees outstanding at 31 March
2024 was £Nil (30 September 2023: £89,000)
abrdn Holdings Limited, which shared
the same ultimate parent as the Manager during the period ended 31
March 2024, received fees for the provision of Company Secretarial
services of £42,000 (31 March 2023: £36,000) during the period. The
balance of secretarial fees outstanding at 31 March 2024 was
£21,000 (30 September 2023: payable of £89,000).
No other related party transactions
were undertaken during the six months ended 31 March
2024.
Further to the public announcement on
23 October 2023, abrdn plc as the former ultimate beneficial owner
of the Manager completed the sale of its European Private Equity
business to Nasdaq-listed Patria Investments on 29 April 2024. The
announcement of and subsequent sale of the Manager of the Company
has no impact on the Interim Financial Statements.
Following the sale transaction, abrdn
Holdings Limited will no longer provide Company Secretarial
services to the Company. These services, with effect from 29 April
2024, are provided by GPMS Corporate Secretary Limited, which
shares the same ultimate parent as the Manager.
|
ALTERNATIVE
PERFORMANCE MEASURES
Alternative performance measures
("APMs") are numerical measures of the Company's current,
historical or future performance, financial position or cash flows,
other than financial measures defined or specified in the
applicable financial framework. The Company's applicable financial
framework includes FRS 102 and the Association of Investment
Companies ("AIC") SORP.
In selecting these APMs, the
Directors considered the key objectives and expectations of typical
investors in an investment trust such as PPET.
Annualised NAV Total Return
Annualised NAV Total Return is
calculated as the return of the Net Asset Value ("NAV") per share
compounded on a quarterly basis, based on reported NAV per share
from inception to 30 September 2023. NAV Total Return is inclusive
of all dividends received since inception and assumes all dividends
are reinvested at the time they are received and generate the same
return as NAV per share during each reporting period. Assuming
dividends are not reinvested results in a annualised NAV total
return of 10.4% since inception.
Discount
The amount by which the market
price per share is lower than the net asset value ("NAV") per share
of an investment trust. The discount is normally expressed as a
percentage of the NAV per share.
|
|
As
at
31
March
2024
|
As
at
30
September
2023
|
Share price (p)
|
a
|
535.0
|
442.0
|
Net Asset Value per share
(p)
|
b
|
784.9
|
777.7
|
Discount (%)
|
c = (b-a) / b
|
31.8
|
43.2
|
Dividend yield
The total dividend per Ordinary share
in respect of the financial year divided by the share price,
expressed as a percentage, calculated at the year end date of the
Company.
|
|
As
at 30 September 2023
|
As
at 30 September 2022
|
Dividend per share (p)
|
a
|
16.0
|
14.1
|
Share price (p)
|
b
|
442.0
|
410.0
|
Dividend yield (%)
|
c=(a/b)
|
3.6
|
3.5
|
NAV total return
NAV TR shows how the NAV has
performed over a period of time in percentage terms, taking into
account both capital returns and dividends paid to shareholders.
This involves reinvesting the net dividend into the NAV at the end
of the quarter in which the shares go ex-dividend. Returns are
calculated to each quarter end in the year and then the total
return for the year is derived from the product of these individual
returns.
|
|
NAV (p)
|
NAV per share (p) as at 30 September
2023
|
a
|
777.7
|
NAV per share (p) as at 31 March
2024
|
b
|
784.9
|
Price Movement
|
c=(b/a)-1
|
0.9%
|
Dividend Reinvestment
1
|
d
|
1.1%
|
NAV Total return
|
e=c+d
|
2.0%
|
1 NAV total
return assumes investing the dividend in the NAV of the Company on
the date on which that dividend goes ex-dividend.
Ongoing charges ratio/ expense ratio
The ongoing charges ratio is
calculated as management fees and all other recurring operating
expenses that are payable by the Company, excluding the costs of
purchasing and selling investments, performance fees, finance
costs, taxation, non-recurring costs, and the costs of any share
buyback transactions, expressed as a percentage of the average NAV
during the period. The ratio also includes an allocation of the
look-through expenses of the Company's underlying investments,
excluding performance-related fees.
The ongoing charges ratio has been
calculated in accordance with the applicable guidance issued by the
AIC.
|
|
Six months
ended
31 March
2024
£'000
|
Year ended
30 September
2023
£'000
|
Investment
management fee
|
a
|
5,710
|
11,213
|
Administrative expenses
|
b
|
641
|
1,234
|
Ongoing
charges *
|
c=a+b
|
12,701
|
12,447
|
Average
net assets
|
d
|
1,199,971
|
1,175,937
|
Expense
ratio
|
e=c/d
|
1.06%
|
1.06%
|
Look-through expenses +
|
f
|
1.78%
|
1.78%
|
Ongoing
charges ratio
|
g=e+f
|
2.84%
|
2.84%
|
*
The interim ongoing charges figure above is
calculated using actual costs and charges to 31 March 2024
annualised for the full financial year.
+ The
look-through expenses represent an allocation of the management
fees and other expenses charged by the underlying investments held
in the portfolio of the Company. Performance related fees, such as
carried interest, are excluded from this figure. This is calculated
over a five year historic average, and is recalculated on an annual
basis based on the previous calendar year.
Over-commitment
ratio
Outstanding commitments less cash
and cash equivalents and the value of undrawn loan facilities
divided by portfolio NAV.
|
|
Six months
ended
31 March 2024
£000s
|
Year ended
30 September 2023
£000s
|
Undrawn
Commitments
|
a
|
663,768
|
651,991
|
Less
undrawn loan facility
|
b
|
(163,336)
|
(197,720)
|
Less
resources available for investment
|
c
|
(27,444)
|
(9,436)
|
Net
outstanding commitments
|
d=a-b-c
|
472,988
|
444,805
|
Portfolio
NAV
|
e
|
1,319,063
|
1,261,995
|
Over-commitment ratio
|
f=d/e
|
35.9%
|
35.2%
|
Share price total return
The theoretical return derived from
reinvesting each dividend in additional shares in the Company on
the day that the share price goes ex-dividend.
Date
|
|
Share price
|
Share price (p) as at 30 September
2023
|
a
|
442.0
|
Share price (p) as at 31 March
2024
|
b
|
535.0
|
Price Movement (%)
|
c=(b/a)-1
|
21.0%
|
Dividend Reinvestment (%)
1
|
d
|
1.9%
|
NAV Total return (%)
|
e=c+d
|
22.9%
|
1 Share
price total return assumes reinvesting the dividend in the share
price of the Company on the date on which that dividend goes
ex-dividend.
For
Patria Private Equity Trust plc
GPMS
Corporate Secretary Limited, Company Secretary
For further information,
please contact:
Patria Private Equity Trust
plc
|
|
Alan Devine
(Chair)
|
via SEC
Newgate
|
The Manager & Company
Secretary
|
|
Alan Gauld (Lead
Investment Manager)
Amber Sarafilovic
(Marketing & IR)
Paul Evitt (Company
Secretary)
|
via SEC
Newgate
via SEC
Newgate
via SEC
Newgate
|
SEC Newgate
|
|
Sally
Walton
|
+44 (0)20 3757 6872
ppet@secnewgate.co.uk
|